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ABSTRACT
More than 200,000 women are diagnosed with breast cancer each year in
the United States, where the majority will undergo a lumpectomy procedure and
then radiotherapy as preventative treatment. Both artificial and tissue transplants
may obscure the detection of cancer recurrence or limit the effectiveness of
radiation treatment. Previous research in our laboratory has been performed to
develop injectable lumpectomy void fillers. This body of work seeks to continue
and further develop the technology of the void fillers and further investigate the
potential of fatty acids in breast tissue engineering.
Literature suggests that lipid peroxidation products from free fatty acids may
have anti-cancerous effects. Linoleic acid is in the family of fatty acids associated
with lipid peroxidation; however, linoleic acid is also associated with growth
promoting eicosanoids which has caused linoleic acid to be considered a cancer
promoting agent. Studies shown here suggest that a high concentration, 100 µM,
of linoleic acid was effective at limiting cancerous proliferation by day 6, and
suggest a complete removal of the cancerous population by day 8, while control
cells remained largely unaffected.

Further studies confirmed the elevated

presence of lipid peroxide products in the inhibited cancerous cell cultures. When
linoleic acid was tested in culture with tamoxifen, the observed inhibition of
cancerous proliferation was greater than either of the treatments alone. This
finding supports the use of linoleic acid in tissue engineered scaffolding.
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Additional work was performed to advance the development of a
lumpectomy scaffolding. An injectable chitosan scaffolding has previously been
developed through the use of a pH shifting technique; however, work described
here continued the scaffolding development by adding gelatin, hyaluronic acid, and
an acid washing step which resulted in the formation of a distinct bilayer. Cells
cultured on the bilayered scaffolding were found to migrate to the boundary
between layers where they proliferated at an accelerated rate compared to uniform
hydrogels. Fatty acids were able to be incorporated into the production of the
hydrogels at a concentration of 400 µM.
Previous researchers in the laboratory had reported adipogenic effects from
linoleic acid. These results were not observed upon further investigation. Linoleic
acid did result in the swelling of human stem cells but did not otherwise
morphologically change the cells. A mixture of conjugated linoleic acid however,
was tested and found to upregulate adipogenic specific markers to a level
indistinguishable from adipogenic controls.
Through the course of this body of research, several advances were made
in the field of test methods for tissue engineering. Work was done towards the
improvement of procedures of multiwell plate readers to allow sterile sampling, the
cytotoxicity of alamarBlue was found and investigated, improvements to previous
lab gas chromatography procedures were made, and analyses of experimental
results indicated the importance of recovery periods in cytotoxicity studies.
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PREFACE
The research behind this dissertation seeks to further previous laboratory
research and literature knowledge on the topic of fatty acids and chitosan
hydrogels with the intention for use in post-lumpectomy patients. Chapter 1
outlines the significance and relevance of breast cancer lumpectomy void fillers.
Chapter 2 provides a thorough literature review on relevant topics. Reviewed
literature topics include breast cancer, breast cancer treatment, breast tissue
engineering, adipogenesis, fatty acids, lipid peroxidation, eicosanoids, scaffolding,
and breast cancer animal models.
The collection and analysis of multiple experiments on linoleic acid’s effect
on cellular culture is shown in Chapter 3. Initial in vitro studies investigated MCF7
and MCF10A cells while further studies added longer time points, more cancerous
cells, and extended time points to analyze metabolic activity of unstressed cells
after having been treated. A final study was conducted to definitively detect the
presence of lipid peroxidation products in cell culture samples after having been
exposed to exogenous linoleic acid.
Literature has shown that polyunsaturated fatty acids which undergo lipid
peroxidation may work in tandem with one another. Chapter 4 investigates the in
vitro effects of treatment with tamoxifen alongside supplementation with linoleic
acid. Several experiments were conducted with the aim of better understanding
the interaction between the two additives. A slide stain histology procedure was

xi

adapted for use in cell culture plates to provide insight on the cellular swelling from
linoleic acid. The importance of observing metabolic activity several days after a
cytotoxic insult was revealed in data analysis. The results from Chapter 4 were
published in the Journal of Histotechnology in 2014.
Previous laboratory members reported adipogenic properties of linoleic
acid, and Chapter 5 seeks to advance this body of knowledge by investigating the
potential of an isomer of linoleic acid, conjugated linoleic acid, and its role in
upregulating adipogenic specific gene expression. There is literature to support
that one isomer of conjugated linoleic acid encourages adipogenesis while another
isomer discourages adipogenesis and may even cause delipidation. Currently
approved supplements of conjugated linoleic acids contain an equal part mixture
of the two isomers, and thus the research purpose was to investigate the mixture’s
role in adipogenesis.
Lumpectomy void filler hydrogel scaffoldings have previously been created
by laboratory members; however, Chapter 6 shows a new production technique
which results in the formation of a distinct outer-layer on the hydrogels. The cellular
and fatty acid eluting properties of this new scaffolding design were tested. A
recently developed hydrogel sectioning technique was used to visualize and stain
the outer-layer. The preparation of multilayered hydrogels was presented at The
Society for Biomaterials in 2014.
Through the course of the research, advances were made to adipose
engineering test methods. These are shown in Chapter 7, which covers the use

xii

of a multiwell plate reader to allow accurate readings while the sample remains
sterile. Resazurin assays were also investigated for their ability to be used
repeatedly or long-term. The refinement of the methylation procedure for the recent
gas chromatography addition to the laboratory capability is shown in Chapter 7.
The information regarding the toxicity of

resazurin was published in

Cytotechnology in 2013. Lastly, Chapter 8 serves to summarize the key findings
from this collection of research, and Chapter 9 gives suggestions and
recommendations for future research projects or goals.
.

xiii

CHAPTER 1
SIGNIFICANCE
It is estimated that over 230,000 women will be diagnosed with breast
cancer in 2014 in the United States (1). Once a person has breast cancer, the
current model for treating cancerous breast tissue is excision of cancerous areas,
then radiotherapy (2). Recent advances in treatment have reduced the breast
cancer mortality rate by 28% from 1991 to 2006 (3). However, 20% of breast
cancer survivors who had a lumpectomy and radiotherapy will still have a
recurrence of breast cancer in the next 10 years (4).

Figure 1: Surgical rates per 100 operations. Data from Pesce 2014 (5).

1

The percentage of young women who undergo a bilateral mastectomy has
seen a rapid increase, from rates of 9.3% to 24.1% from 2003 to 2010, as shown
in Figure 1. While there is a paradigm shift in the treatment of under 45-year-old
women, the overall lumpectomy rates for women in general have remained
constant during the same time period, from 67.7% to 66.4% (5). The percentage
of patients who opted for an immediate breast reconstruction procedure grew at a
rate of 5% per year from 1998 to 2008. By 2008, 37.8% of women received an
implant immediately after tumor removal. (6)
Silicone implants, which are often used to fill a void, do not aid in the
prevention of cancer recurrence. Specifically, silicone implants may reduce the
effectiveness of radiation treatments and delay detection of dorsal cancer
reoccurrence (7). One study found 15% of women with immediate breast
reconstruction had early complications due to the implant. The most common,
21%, of complications was capsular contracture. The study found a correlation
between irradiation with silicone implants and increased complications (7). A
natural tissue construct should reduce the number of patients needing to be
readmitted.
Alternatives, such as musculocutaneous flaps, transverse rectus abdominis
muscle, and latissimus dorsi flaps, have been used as reconstructive materials (7)
(8). However, these are better suited for the larger voids created by mastectomies,
rather than lumpectomies. Autologous implants do not help solve the long-term
20% rate of breast cancer reoccurrence either. Additionally, autologous adipose
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tissue transplants include micro deposits of serum calcium from fat resorption that
may obscure mammography and interfere with tumor detection (9). These
autologous implants cause loss of tissue from a secondary site in the patient,
leading to additional complications. The tissue engineering field may offer some
other options for these cancer survivors.
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CHAPTER 2
LITERATURE REVIEW
2.1 Anatomy of the Human Breast
Breast tissue comprises two tissue types: stromal and epithelial.

The

stromal tissue is the vascular body of the breast and is predominantly adipose
tissue (10). The epithelial tissue is predominantly glandular tissue, and gives the
breast its milk-producing function (11). The breast further comprises the areola and
the nipple, on the external surface. Ducts lead from the nipple to 15-20 lobules
(10). These lobules are formed by lobular cells which are types of epithelial cells.
In terms of tissue engineering, the milk-producing function of the breast is of minor
importance, as patient survivability is the major concern. For this reason, the focus
of breast tissue engineering is on adipose tissue rather than epithelial tissue.
Additionally, epithelial cells may increase the threat of cancer reoccurrence.

2.2 Breast Specific Cancers
Breast cancers are strictly defined as any type of cancer located in the
breast. However, a common breast cancer involves lobular epithelial cells which
begin to proliferate without regard to contact inhibitors (12). This behavior is often
the result of deoxyribonucleic acid (DNA) damage to oncogenes, i.e. the genes
that control cell proliferation and differentiation. Cancerous tumors are thought to
be more common with risk factors including gender, age, weight, family history,
childbearing history, and environmental contributors (13) (14). The majority, 85%,
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of breast cancers form in the ducts, from the nipple to the lobules, with most of the
remaining cancers being formed in the lobules (14). Figure 2 by Polak and Habal
shows an overview of typical breast cancer progression (15).

Figure 2: Progression of lobular epithelial breast cancer. From Polyak 2007 (15).
Normal healthy breast cells are generally present when the epithelial cells
are in a confluent monolayer along the basement membrane. Hyperplasia is
normally a benign tumor and is not considered cancerous. If the cells start to
deform and show characteristics not inherent to typical epithelial cells, they are
called atypical and the tumor is said to be pre-cancerous. When the epithelial cells
lack contact inhibition and form a compact mound of cells, this is called an in situ
cancer, or Stage 0. Finally, if the cancer cells break out of the basement membrane
to surrounding tissue, it is an invasive, or Stage I, breast cancer (15).
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2.2.1 Breast Specific Cancer – Staging Systems
Classification of breast cancers includes two groupings, the pathologic
grouping (identified as Tumor, lymph Nodes, Metastasis, or TNM) and the stage
grouping (identified as the Roman Numeral Staging) (16) (17). The Roman
Numeral Staging system is outlined in Table 1. There are other less common
variables not always included in the TNM grading scale, which include Certainty,
Grade, Resection, invasion to Lymphatic vessels, and invasion to Veins.
Table 1: Roman Numeral Staging System
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Table 2:The TNM grading system

The major variables in the TNM grading system as well as their commonly
given values are shown in Table 2. However, there are frequently other prefixes
attached to the TNM system as well. These prefixes include either clinical or
pathological sample, chemotherapy, recurrent tumor, or autopsy sample, in
lowercase. As an example, apT4 apN2 M1 G4 means the cancerous tissue sample
was a pathological sample from an autopsy, which was found to be into the chest
wall, in distant lymph nodes, in distant organs, and with a grade of 4. A grade of 4
is notably subjective and means highly cancerous in morphology of the cell line.
Each class can also be broken down into subclasses such as T1a or N2b. The full
details on the TNM ranking system change every few years with the most recent
edition of the system, i.e. Edition 7, published in 2010 (18).
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2.2.2 Breast Specific Cancers - Classifications
The staging systems, both Roman Numeral and TNM, do not indicate which
type of cancer a patient has, but merely give insight into the progress of the
cancerous cells. There are several frequent classifications of mutations which are
seen in all types of breast cancer. Sometimes breast cancer cells are classified as
node negative or node positive, but these are misnomers. This classification does
not describe breast cancer cell phenotype, but rather the progression of the cancer
and migration to the lymph nodes.
The presence, or lack of presence, of an estrogen receptor (ER) epitome
on the cancerous cell line is perhaps one of the most commonly used phonotypic
classifications used to segregate cancerous cells. As the name implies, some
mutations will lose all estrogen receptors while others (85%) will maintain their
responsiveness to estrogen. This characteristic is important to identify as it
radically changes how the patient should be treated and how to design a tissue
engineered construct. The loss of estrogen receptors has been associated with
mutations in various genes including: LIV-1, TFF3, GATA3, c-myb, and BTG2 (19).
A study by Sotiriou and coworkers, found that menopausal status of a patient is
not correlated with ER status of breast cancer (19). This was an important finding,
as menopausal status was once considered a risk factor for ER status. The ER+
status can be further divided into luminal 1, luminal 2, and luminal 3, while the ERstatus can be divided into basal 1, basal 2, and HER2/neu phenotypes.
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An extension of the estrogen receptor phenotype is the progesterone
receptor phenotype (PR). This phenotype is classified in a similar manner to
estrogen, where PR+ indicates the responsiveness of the cell line to progesterone
and PR- indicates the lack of responsiveness to progesterone. Another type of
classification is human epidermal growth factor receptor 2 (HER2), which is also
known as neu, ErbB2, CD340, or p185. In the case of HER2, HER2+ means up
regulation, whereas HER2 means normal regulation of the growth factor. Thirty
percent of breast cancers are HER2+ which has a more difficult treatment route
than other breast cancer phenotypes. HER2+ cells are more likely to become
metastasized and spread to additional locations (19). Sotiriou and coworkers give
a graphical depiction of the genetic diversity of several wild type cancers, and their
grouping into phenotypes as seen in Figure 3 (19).
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Figure 3: Genetic diversity of wild type breast cancers. Dendrogram by Sotiriou
2003 (19).
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2.2.3 Breast Specific Cancers - Cancer Cell Lines
Recent studies have suggested thousands of genes may contribute to
breast cancer pathophysiology (20). Yet if one wishes to study cancerous behavior
in vitro, there must be cancerous cells lines which will model the likely behavior of
a wild type cancer in a patient in vivo. A study by Neve and coworkers studied the
phenotypes of 51 commonly used cancer cell lines, shown below in Table 3 (20).
It is important to note several of the cell lines included are not adenocarcinomas.
MCF10A and MCF12A were collected during reductive mammoplasty. These cells
are proliferative but maintain their contact inhibition and are, therefore, commonly
used as controls against treatment options. The productions of cancerous cell lines
are all similar. The cancerous cells are not inhibited by contact and will continue to
proliferate after a confluent monolayer has been established. In the presence of
low calcium medium, a newly dividing cell will rapidly and freely float in the medium.
This occurrence is due to the Ca2+ ion requirement of the binding ligands, which
bind the cells to the extracellular matrix. The floating cells are captured and the
monolayer need not be disturbed. This process allows cultivation of these cell lines
without trypsinization. Studies have shown some cell lines maintain their qualities
for up to 25 doubling times (20).
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Table 3: Current in-vitro breast cancer cell lines models and their characterizations.
adenocarcinoma (AC), ascites ﬂuid (AF), anaplastic carcinoma (AnCa),
acantholytic squamous carcinoma (ASC), Basal A (BaA), Basal B (BaB),
carcinoma (Ca), chest wall nodule (CWN), ductal carcinoma (Duc.Ca), ﬁbrocystic
disease (F), invasive ductal carcinoma (IDC), invasive lobular carcinoma (ILC),
inﬂammatory (Inf), lymph node (LN), luminal (Lu), metaplastic carcinoma (MC),
metastatic lobular carcinoma (MLCa), normal (N), papillary (Pap), not done (ND),
primary breast (P.Br), pleural effusion (PE), skin (Sk), White (W), Black (B),
Hispanic (H), and East Indian (EI). Table from Neve 2006 (20).
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2.2.4 Breast Specific Cancers – Treatment Options
The treatment of breast cancer depends on both the TNM stage and the
cancerous cell phenotype. The National Cancer Institute held a summit to
standardize treatment options for primary breast cancers (2). The summit’s
recommendation indicates that the cancer must first be classified into low risk,
intermediate risk, or high risk. The classification for node negative cancers, where
the cancer has not yet progressed into any lymph nodes, follows the
recommendations shown in Table 4. The National Cancer Institute suggests that
if one or more of the attributes listed in Table 4 can be attributed to the cancer,
then it is classified in the higher risk category. This means a small tumor of grade
G1 that is ER- is considered high risk.
Table 4: Risk ranking system for node negative breast cancers.

Age grouping was noted in the summit to be counterintuitive; i.e., young
patients are considered high risk because they are at a higher risk of having a
secondary occurrence of cancer later in life (2). It was recommended that a patient
be treated with tamoxifen and/or chemotherapy, depending on the risk level and
progression of the cancer. Since this time, other cell types have been identified
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and the options have changed slightly. Resection of the tumor pre-metastasis is
now the standard of care followed by the recommendations listed in Table 5.
Table 5: Treatment suggestions for breast cancer based on risk.

The approved chemotherapeutics suggested by the National Cancer
Institute from Table 5 are shown in Table 6. Table 6 shows a list of all medical
drugs, and their indications, which have FDA approval for use in breast cancer
patients according to the National Institutes of Health in 2014, and their approved
indications (21). These drugs function in a variety of ways including receptor
binding, estrogen inhibition, cytotoxicity, intercalation of DNA, and antimitotic
effects (22) (23) (24).
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Table 6: List of FDA approved drugs for the treatment of breast cancer.
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Since the inclusion of erbB-2, or HER2, new challenges have arisen. These
are the triple negative phenotypes, that is, when the cancerous mass does not
express ER+, PR+, or HER2+ phenotypes. Approximately 15% of all breast cancers
are triple negative, with a higher percentage seen with patients of African descent
(25). Triple negative phenotypes have driven the use of antibodies, cellular
messenger inhibitors, and other nontraditional treatment methods (26) (27).
After the removal and successful treatment of breast cancer, reconstruction
techniques are used frequently with the combination of tamoxifen as a prophylaxis
measure. Tissue reconstruction techniques following breast tumor removal include
cellular and acellular options, and immediate and delayed options. The course of
action depends on the presence of necrotic tissue, scarring, and/or ongoing cancer
treatment (28) (29). Acelluar options include breast prostheses, which may be
worn outside the body to provide the appearance of a breast or breast implants.
Tissue expanders are employed to prepare the site for an implant; an expander is
a silicone bag that is implanted subpectorally. The expander is filled with saline
incrementally, to slowly stretch and expand the skin. Once a large enough pocket
has been created at the defect site, an implant can be placed. Silicone implants
are saline or gel filled and are implanted directly into the defect site. Gel-filled
silicone implants have problems, particularly with leakage, leading to their declined
usage. Additional complications include, but are not limited to, capsular contracture
and the concealment breast tumors (28) (30) (31).
16

Cellular reconstructive options include musculocutaneous flaps, transverse
rectus abdominis muscle, and latissimus dorsi flaps (7) (8) (28) (29) (30) (31) (32)
(33) (34). These options have similar complications to those of other autologous
transplants, which prevent their widespread acceptance. There are other cellular
options, which include adipose tissue transfers and collagen injections (35) (36)
(37). Adipose grafts make the most logical sense considering the breast comprises
predominately adipose tissue. However, this approach has been met with variable
success (38) (39). It is common to see significant resorption of transplanted tissue
over time, resulting in up to 60% of the graft volume. Resorption could be due to a
lack of vascularization or due to improper fatty acid composition in the triglycerides
swelling the adipose tissue (38) (40). Because of these complications, breast
tissue engineering strategies must incorporate new methods for natural breast
reconstruction (41)

2.3 Breast Tissue Engineering
Breast reconstruction techniques using the patient’s own tissue tend to
produce better results (42) with fewer complications (43). The transplantation of
autologous tissue alone results in poor outcomes, where 60% of the graft volume
is reduced due to resorption (44) (45) (46) (47). Moreover, mature adipocytes do
not proliferate because they are terminally differentiated (42) . Autologous adipose
tissue transplants include micro deposits of serum calcium from fat resorption that
may cloud mammography results and interfere with tumor detection (9). For these
17

reasons, the study of breast tissue engineering has focused on either the
construction of tissue implants ex vivo from the patient’s preadipocytes, or on
encouraging the differentiation of stem cells in situ. Either focus requires the
understanding of the composition of adipose tissue, the adipogenic pathway, and
the awareness of cancerous implications.

2.3.1 Breast Tissue Engineering - Components of Adipose Tissue
The growth and/or creation of adipose tissue are the targets for many breast
tissue engineers. Adipose tissue is a type of connective tissue in animals that was
once thought to be inert and only used for storage of energy in fats. Adipose tissue
is now recognized to be an integral part of the endocrine system and produces
estrogen, resistin, and eicosanoids (48). Although there are many types of adipose
tissues, including subcutaneous fat, visceral fat and yellow bone marrow fat, they
all comprise the same cell types. Adipose tissue consists predominately of
adipocytes, with fibroblasts and endothelial cells. The composition of adipose
tissue changes with age. Baker sampled adipose tissue from 37 different patients
in 1969 and provided insight regarding the adipose tissue composition (49). His
findings are detailed in Table 7.
Baker’s autopsy studies indicate the increasing concentration of lipids and
the decreasing cellular nature of adipose tissue with age. However, even though
these data indicate the presence of lipids, adipose tissue has other characteristics
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that tissue engineers may use. Adipose tissue is host to a stem cell class known
as preadipocytes. These stem-like cells can differentiate into the fibroblasts and
adipocytes needed for new tissue (48). Mature adipocytes are thought to be
terminally differentiated and no longer proliferative (42). However, adipocytes
consist of up to 90% lipids in their cytoplasm and will swell and contract based on
the dietary intake of the animal. With this contraction and expansion of tissue, the
contraction and expansion of the vascularization is necessary. This continual
process may be the reason for the abnormally high concentration of stem cells in
adipose tissue. Regardless of why these stem cells exist, engineers can make use
of them. Rather than injecting stem cells into a location, or culturing stem cells in
vitro before implantation, the focus has been towards acellular scaffolding implants
to encourage tissue regrowth. Even though adipose tissue contains fibroblasts and
endothelial cells, much of the tissue engineering focus is on preadipocytes and
adipocytes (50) (51). In order to engineer adipose tissue, one must understand the
adipogenic pathway.
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Table 7: Composition of adipose tissue. From Baker 1969 (49).

2.3.2 Breast Tissue Engineering - Adipogenic Pathway
Although the physiological mechanism for the creation of adipocytes in vivo
is not known for certain at this time, it appears adipocytes have the same lineage
as fibroblasts (48). The molecular events causing the differentiation of embryonic
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stem cells to adipocytes cells remains to be discovered (48). A depiction of the
adipogenic pathway is shown in Figure 4. Even though it is not common, new
adipocytes are created in the animal body during weight gain (52) (53) (54).
Adipose tissue naturally has preadipocytes, which are thought to differentiate from
mesenchymal stem cells and/or adipogenic stem cells, and can be further
differentiated into mature adipocytes (55) (56) (57) (58) (59) (60). For the cell to
further differentiate, it must first cease proliferation.
Growth arrest is normally achieved through contact inhibition; however,
there are cases where differentiation may proceed without cell to cell contact (48).
Pairault and Green have shown that preadipocytes, 3T3-F442A, which can no
longer proliferate due to restriction of a hydrogel, can still differentiate (61).
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Figure 4: Adipose differentiation from pluripotent mesenchymal stem cells. Figure
from Gregoire 1998 (48).
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Both CCAAT/enhancer binding protein α (C/EBP-α) and peroxisome
proliferator-activated receptors (PPAR-γ) have been shown to activate adipocytespecific genes (62). C/EBP-α-estrogen receptor fusion protein was shown by
McKnight and coworkers to stop cell growth (62). Altiok has shown that PPAR-γ
expression is sufficient to induce growth arrest in fibroblasts and preadipocytes
through the phosphorylation of the DP-1 unit in the E2F/DP-1 complex (63). For
these reasons, researchers typically monitor one or both of these genes when
assessing adipogenesis.
Peroxisome proliferator-activated receptors are common to many cell types
and control cellular development and differentiation (64) (65). The three types are
as follows: α, which is found in liver, kidney, heart, muscle, adipose tissue and
elsewhere; β, which is expressed in many tissues but mostly in brain tissue,
adipose tissue, and skin tissue; and γ, which consists of three subtypes within the
γ category. These subtypes are γ1, γ2, and γ3. They are encoded by the same
gene but expressed through alternative splicing. Subtype γ1 is expressed in nearly
all tissues; γ2 is expressed mostly in just adipose tissues; γ3 is expressed in
macrophages, large intestine, and white adipose tissue (66). These are
summarized in Table 8.
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Table 8: Types of peroxisome proliferator-activated receptors.

Soon after contact inhibition, human primary preadipocytes begin to
differentiate. The ability of cell-cell contact to trigger differentiation in the absence
of cell proliferation was shown by inhibition of mitosis with cytosine arabinoside
(67). The preadipocytes start to change morphology and swell, reducing the actin
and tubulin expression (68). These changes are critical to the differentiation
process and will occur even if triglyceride synthesis is blocked by the deprivation
of biotin (69).

2.3.3 Breast Tissue Engineering – Methods
Much of the focus in breast tissue engineering is on the production of
preadipocytes and adipocytes (50) (51). Most attempts made in the field can be
split into two categories, either ex vivo culturing of cells followed by implantation,
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or in situ tissue formation (32). These two methods share common tools and
technology for both strategies. Specific cell lines are often employed in vitro to
determine how primary cells will act in vivo. Scaffolding provides the 3D culture
environment for cell line or primary cells, and, depending on the application, growth
factors can be incorporated.
The harvesting and testing of mature adipocytes is difficult, due to their
swollen lipid nature. These cells tend to be traumatized by mechanical forces of
aspiration, resulting in approximately 90% damaged cells. If implanted, the
remaining 10% tend to form cysts or simply necrose after injection. Moreover,
mature adipocytes cannot be expanded ex vivo to obtain greater cell numbers
because they are terminally differentiated (32). However, preadipocytes are
precursor cells that differentiate into mature adipocytes and can be seeded onto
scaffolding where they can proliferate and differentiate to promote the formation of
adipose tissue (70). Preadipocytes readily expand in culture, are mechanically
stable, and can easily be obtained via fat biopsies or liposuction (40) (71).
There are a number of preadipose cell lines used to model in vivo primary
cell behavior. The most common cell lines include 3T3-F442A, OB17, 3T3-L1, NIH
3T3, CH310T1/2, 3T3- C2, and TA1 (48) (72). The NIH 3T3 cell line series consists
of murine embryonic fibroblasts, with each modifier of 3T3 indicating a unique
variation from the original 3T3. It has been observed that in vitro cell lines do not
always behave similarly to native preadipocytes. Amri and Kuri-Harcuch observed
an increase in DNA synthesis preceding the expression of mRNA (messenger
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ribonucleic acid) adipocytic markers in 3T3 cell lines, while they noted an inhibition
of DNA synthesis that blocked the differentiation pathway (73) (74). However, DNA
synthesis is not necessary for primary human adipose tissues (75). These primary
cells could go through this critical step of DNA synthesis in situ before removal
from the host tissue and testing, leading to this discrepancy (48).
Acellular tissue engineering methods tend to focus on the recruitment of
surrounding, resident preadipocytes to the scaffold. This approach requires
consideration of the choice of scaffolding, animal model, and growth factors. For
example, many researchers have studied Matrigel, the reconstituted basement
membrane of a mouse tumor. Researchers have shown it to induce migration,
proliferation, and differentiation of preadipocytes when supplemented with
fibroblast growth factor 2 (75) (76) (77) (78). These results also indicate that
endothelial cells are recruited, but it is unclear if angiogenesis drives adipogenesis,
or if adipogenesis drives angiogenesis. Matrigel is common to adipose tissue
engineering; however, there are many other scaffolding choices, including
synthetic polymers and decellularized extracellular matrices.
Other concerns are raised with the use of scaffolding and adipocytes. The
removal and detection of cell viability becomes difficult when cells have migrated
to the remote, interior areas of the construct. Accordingly, viability detection
methods are limited. One method involves the quantification of medium glucose
levels in an in vitro tissue culture. Glucose uptake is not specific to aerobic or
anaerobic respiration, however, and should not be used as the sole indicator of
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viability. Another detection method is the alamarBlue®, or resazurin, detection
method. Resazurin performs a redox reaction at the end of the electron transport
chain, which may then fluoresce, allowing detection (79) (80).
Fatty acid analysis is common, as adipocytes have large amounts of lipids.
Detection of fatty acids is complicated and is described in more detail in the
detection method section. Briefly, the most common fatty acid analysis involves
processing cellular lipid content into methylated free fatty acids, which are then
loaded on a liquid-gas chromatography-fused silica column and detected with a
flame ion detector.
Reverse transcription-polymerase chain reaction (RT-PCR) is not a unique
method to breast tissue engineering analysis but is worth mentioning, as there is
some confusion in the field. A commonly used measure of adipocyte differentiation
is lipoprotein lipase production (57) (81). Lipoprotein lipases are produced by
mature adipocytes and control lipid accumulation (82) (83). Lipoprotein lipase
production can be detected as soon as growth arrest occurs and does not require
the addition of adipocytic differentiation agents (73) (84). Although lipoprotein
lipase mRNA is commonly monitored during adipogenesis, lipoprotein lipases are
not exclusive to adipocytes. Lipoprotein lipases can be produced by
cardiomyocytes as well as macrophages (85) (86). Therefore, PPAR-γ and C/EBPα genes are better and more reliable adipogenic-specific RT-PCR amplicons (48).
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While select growth factors may be beneficial in most tissue engineering
applications, they may be detrimental to breast tissue engineering. Tissue growth
factor β (TGF-β), for example, is widely used in most tissue engineering
applications to encourage proliferation, but is a potent inhibitor of adipocyte
differentiation (59) (87) (88). These discrepancies warrant further investigation.

2.3.4 Breast Tissue Engineering – Growth Factors
All preadipose cell lines exhibit some degree of spontaneous conversion
when grown in the presence of fetal calf serum, even without the presence of any
other additive. This behavior indicates serum is integral to the differentiation
process; however, these components are neither well characterized nor easily
controlled (48). Although the serum additives vary, it is generally recommended
to use insulin-like growth factor (IGF-I) (89) (90), insulin (58) (91), and a
glucocorticoid (92) for induction of differentiation in either serum or serum-free
medium. A common additive known as an adipogenic cocktail was established by
Rubien and coworkers and contains dexamethasone, methylisobutylxanthine, and
insulin or insulin-like growth factor 1 (IGF-1) (48). Dexamethasone is a synthetic
glucocorticoid and, with OB1771 preadipocytes, has been shown to increase the
metabolism of arachidonic acid (20:4, ω-6), leading to an increased production of
cyclic adenosine monophosphate (cAMP) (93). Methylisobutylxanthine amplifies
insulin and IGF-1 by inhibiting phosphodiesterase activity (94).
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Retinoic acid affects various differentiation processes including terminal
events of the adipocyte differentiation cascade. Retinoic acid, therefore, has been
thought to have a critical role in the adipocyte differentiation process. However,
retinoic acid may not be necessary and could actually inhibit adipocyte
differentiation. Differentiation of preadipocytes and primary porcine preadipocytes
has been inhibited when cultured with supraphysiological concentrations of retinoic
acid (95) (96).
Some fatty acids have also shown efficacy in affecting the differentiation of
adipocytes. Fatty acids can control the expression of particular genes, which
encode regulatory proteins involved in their own metabolism. In particular, fatty
acids appear to be involved in the regulation of PPARs, in addition to other
transcription factors (97) (98). Moreover, preadipocytes supplemented with oleic
acid can accumulate large amounts of lipid fairly rapidly in vitro (99), while the
addition of linoleic acid to culture medium of preadipocytes can also result in
significant lipid accumulation within the cells (100). Conjugated linoleic acid has
been shown to induce differentiation in adipose tissue (101) (102) and eicosanoids,
a byproduct of some fatty acids, and is associated with the proliferation of cells
from human endometrium (103).
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2.3.5 Breast Tissue Engineering – Cancerous Implications
Cancer recurrence is of major concern in breast tissue engineering because
the primary indication of breast tissue engineered constructs is for post
mastectomy patients. However, this primary indication also opens an opportunity
for tissue engineering. Cancer cells sometimes process additives and growth
factors differently than their normal, healthy cell counterparts. Begin and coworkers
reported that the addition of polyunsaturated fatty acids to cultures of cancer cells
supplemented with 10% fetal calf serum resulted in a significant increase in the
generation of thiobarbiuric acid-reactive lipid peroxidation products and a parallel
increase in cancer cell death, whereas normal cells appeared to be resistant (104).
Dietary conjugated linoleic acid can also induce apoptosis of premalignant
lesions while having no apparent effect on healthy cells (105). Conjugated linoleic
acid fed to animals during mammary gland development and maturation appeared
to have long-lasting protective effects on mammary carcinogenesis (106) (107).
Given some fatty acids’ ability to prevent cancer, others’ ability to encourage
adipogenesis (97) (98), and the ability of eicosanoid byproducts to induce healthy
cell proliferation and wound healing (103), fatty acids are potential growth factors
and may have a lot to offer the breast tissue engineering field.
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2.4 Fatty Acids
The effects of fatty acids on cancerous cells and healthy cells vary
according to the fatty acid. A case study by Bagga and coworkers in 2002 found
fatty acid

concentrations

often

differ when

comparing cancerous and

noncancerous mammary tissues (108). Conjugated linoleic acids reduced
proliferation of mammary tumor cells in vitro (109) (110) and in vivo (111). In
cultured mammary epithelial cell organoids, conjugated linoleic acids inhibited cell
growth (105). Most importantly to breast tissue engineers, conjugated linoleic acids
have been shown to induce markers of differentiation in adipose tissue (101) (102).
For these reasons, the investigation into fatty acids is of increasing interest in
breast tissue engineering.

2.4.1 Fatty Acid – Types and Classification
Biological fatty acids are stored in units of three and attached to a glyceride
backbone. This storage unit is called a triglyceride and is colloquially known as a
fat molecule which can be seen in Figure 5. When speaking of a fatty acid, one
only refers to one of the chains of the triglyceride (112). An ester bond between
the each fatty acid and the glycerol backbone is frequently broken and the fatty
acid becomes known as a free fatty acid. Free fatty acids are also found in the
cellular membranes (112). The nomenclature describing a free fatty acid is derived
as follows: the number of carbons in the chain, including the carboxylic carbon, are
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counted and listed numerically, the number of double bonds where the carbon
atoms have been sp2 hybridized are listed, and, finally, the location of the last
double bond, starting from the last carbon, or omega carbon, is listed. The naming
of the free fatty acid in Figure 5 would be shown as 18:2, ω-6, also known as
linoleic acid

Figure 5: Depiction of a typical triglyceride and linoleic acid.
Biologically, only even numbers of carbons in free fatty acids are observed.
This fact comes from the process of lipid formation. In animals, the process for
fatty acid synthesis is almost as complex as protein formation from mRNA, but is
often less studied (112). Fatty acid synthase is a dimeric enzymatic protein which
helps catalyze the synthesis of fatty acids in a fashion similar to transfer RNA
(tRNA). Each dimer comprises three domains, and each domain has three more
subunits, with the exception of the third domain, which has only a single enzymatic
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subunit to release the final product, palmitate. The production of fatty acids starts
with the substrates acetyl-CoA and an acetyl group attached to the fatty acid
synthetase enzyme. The following enzymes produce the base structure: butyrylacyl carrier protein (ACP), acetyl-coenzyme A (CoA) carboxylase, malonyl
transacylase,

β-ketoacyl-ACP

synthase,

β-ketoacyl-ACP

reductase,

β-3-

hydroxyacyl ACP dehydrase, and 2,3-trans enoyl ACP reductase. The fatty acid
chain is four carbons in length, with the carboxylic acid group attached to the fatty
acid synthetase. The chain is grown to 16 carbons by the addition of a molecule,
malonyl-ACP, containing exactly two units of carbon. Each elongation step uses
up two nicotinamide adenine dinucleotide phosphates (NADPHs). Because the
process starts with a two carbon substrate and only adds two carbons at a time,
odd numbered fatty acids are not seen in nature (112).
The simplest of the common fatty acids are saturated fatty acids, meaning
they are only hydrocarbon chains with sp3 hybridized carbons. The most common
saturated fatty acids are palmitic acid (16:0) and stearic acid (18:0), with others
including caprylic acid (8:0), capric acid (10:0), lauric acid (12:0), myristic acid
(14:0), arachidic acid (20:0), behenic acid (22:0), lignoceric acid (24:0), and cerotic
acid (26:0) (113). When the fatty acid has a single sp2 hybridized carbon, the fatty
acid is known as a monounsaturated fatty acid. This single carbon phenomenon
commonly occurs near the middle of the fatty acid chain, resulting frequently in the
following fatty acids: palmitoleic acid (16:1 n-7), cis vaccenic acid (18:1 n-7), and
oleic acid (18:1 n-9), with ‘n’ being similar to ‘ω’ but more common to
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monounsaturated fatty acids, while ‘ω’ is more common in polyunsaturated fatty
acids (112).
Another type of fatty acid is the polyunsaturated fatty acid, which has more
than one sp2 hybridized carbon, allowing at least two π bonds. Although some rare
fatty acids have sp2 hybridized carbons close enough to allow delocalized
resonance of the electrons, it is standard for a polyunsaturated fatty acid to have
at least three carbons between the start of the double bonds. This polyunsaturated
fatty acid category is further broken down into omega-3 fatty acids and omega-6
fatty acids. Sometimes omega-9 fatty acids are mentioned in the literature, but the
only common omega-9 fatty acid is oleic acid (18:1 ω-9) and is monounsaturated.
The omega-3 polyunsaturated fatty acids include aicosapentaenoic acid (20:5 ω3), docosahexaenoic acid (22:6 ω-3), docosapentaenoic acid (22:5 ω-3), and α–
linoleic acid (18:3 ω-3). The omega-6 fatty acid family includes linoleic acid (18:2
ω-6), arachidonic acid (20:4 ω-6), and γ-linoleic acid (18:3 ω-6) (112) .
Double bonds in which the two sigma bonds surrounding the π bond are an
acute angle are termed cis conformation while obtuse angles are known as trans
conformation. Select unsaturated fatty acids can be classified as trans fats. Nearly
all π bonds made by animals are cis in conformation. Pi bonds do not allow the
rotational freedom that σ bonds allow. Beef, lamb, and dairy-derived foods are the
only natural sources of trans fats (114) (115) (116). One of the most unique and
common trans fat is conjugated linoleic acid. Conjugated linoleic acids are a group
of isomers which are similar to linoleic acid (18:2 ω-6), but whose π bonds between
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sp2 hybridized carbons are within two carbon atoms of one another, allowing the
free resonance of electrons (112).
The final type of fatty acid is the essential fatty acid, which are fatty acids
that cannot be created by the human body but are required by the human body.
This category includes linoleic acid (18:2 ω-6), α-linoleic acid (18:3 ω-3), and
arachidonic acid (20:4, ω-6) (112). Even though linoleic acid is an essential fatty
acid, Americans in particular are in no short supply. Kris-Etherton and coworkers
discovered that linoleic acid accounts for 85% of total fatty acids in American diets
(113) .

2.4.2 Fatty Acids – Cellular Effects
Numerous epidemiological, experimental, and ecological studies have been
conducted to evaluate the relationship between dietary fatty acid and breast cancer
risks (117) (118). Biopsies from various breast tissues have shown some of the
earliest insights into fatty acids’ effects on tissues. Analyses of normal breast tissue
samples have shown that the fatty acids found most commonly in the highest
concentrations within the samples are oleic acid, palmitic acid, linoleic acid, and
stearic acid (119) (120). Analysis of cancerous mammary tissue has led to the
concept that increased levels of linoleic acid (18:2 ω-6) and arachidonic acid (20:4,
ω-6) are associated with increased risk of breast cancer (108) (119) (121) (122),
while increased levels of α-linoleic acid, eicosapentaenoic acid, docosahexaenoic
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acid, and conjugated linoleic acids are associated with decreased risk of breast
cancer (108) (119) (121) (123). A case study by Klein and coworkers examined
fatty acid levels in breast adipose tissues and found α-linoleic acid provided a
statistically significant protective growth effect on breast cancer (123). The same
researchers were unable to show any other fatty acid relationships with breast
cancer. In contrast, London and coworkers reported no consistent patterns
between breast cancer risk and any fatty acids (124).
In an effort to reveal better insight into the relationship between fatty acids
and cellular behavior, in vitro culturing of cell types has been extensively performed
by multiple researchers. In general, these studies have revealed cancer and fatty
acid relationships, which can be described in three categories: omega-6
polyunsaturated fatty acids, conjugated linoleic acids, and all other fatty acids.
It appears all fatty acids, with the exception of omega-6 polyunsaturated
fatty acids and conjugated linoleic acids, inhibit breast cancers while having little
to no effect on healthy cellular growth. The broad categories of saturated fatty
acids have been shown to inhibit breast cancers (125) (126). The omega-3
polyunsaturated fatty acids have also been shown to inhibit breast cancer (119)
(127). However, the omega-9 unsaturated oleic acid (18:1 ω-9) has been shown
in at least one study to promote MDA-MB-231 cancer cells at low concentrations,
less than 3.5 µM. Above that concentration, oleic acid was inhibitory (127). But, all
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fatty acids tested, again with the exception of omega-3, had little effect on healthy
cellular growth (104).
In the polyunsaturated fatty acids (ω-6) category, linoleic acid (18:2, ω-6) is
the most common and is the parent of many other omega-6 acids. Arachidonic
acid (20:4, ω-6) is a degradation product of linoleic acid, and is created by the
enzymes Δ6 desaturase, elongase, then Δ5 desaturase (128). Arachidonic acid
(20:4, ω-6) is instrumental in bodily functions ranging from brain function to muscle
growth (108). Arachidonic acid (20:4, ω-6) and linoleic acid are both substrates for
the production of eicosanoids. Eicosanoids are associated with the proliferation of
nearly all cultured cells derived from human endometrium, affecting both healthy
cells and cancerous cells (129). In vitro studies have suggested increased linoleic
acid and/or arachidonic acid (20:4, ω-6) levels may promote cancer cell growth
(110) (130) (131) (132). However, while linoleic acid has been shown to be
stimulatory of cancerous cell growth at concentrations of 1.8-70 µM (110) (130), it
has been shown to be inhibitory at levels greater than 70 µM and at longer
incubation times (130) .
Conjugated linoleic acids are found in beef and lamb as well as dairyderived foods (114) (115) (116), with the predominate isomer being c9-t11
conjugated linoleic acid (CLA), termed rumenic acid (116) (133) (134). These
conjugated linoleic acids constitute a group of isomers of linoleic acid (18:2 ω-6)
whose bonds allow for resonance of π-orbital electrons giving a unique behavior.
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Conjugated linoleic acids have been shown by a great body of literature to
modulate body composition, especially by reducing the accumulation of adipose
tissue, in experimental animals. In mice, rats, pigs, and humans, dietary
conjugated linoleic acids reduced adipose tissue depots (135) (136) (137) (138).
In cultured cells, conjugated linoleic acids reduced proliferation of mammary tumor
cells in vitro (109) (110) and in vivo (111). In cultured mammary epithelial cell
organoids, conjugated linoleic acids inhibited cell growth (105). Most importantly
to breast tissue engineers, conjugated linoleic acids have been shown to induce
markers of differentiation in adipose tissue (101) (102). These discrepancies in
actions by fatty acids can perhaps be explained by eicosanoids and/or lipid
peroxidation. Eicosanoids are linked with overall cell growth, while lipid
peroxidation is the process that is presented to explain why polyunsaturated acids
slow or kill cancerous cells (103) (129) (139).

2.4.3 Fatty Acids – Tissue Induction
Omega-6 polyunsaturated fatty acids have been linked with growth of cells
derived from human endometrium (103), normal breast epithelial cells and
fibroadenomas (129), and breast cancer cells (137), through eicosanoid products.
Other fatty acids have been able to induce adipogenesis (101) (102). These
discoveries suggest fatty acids can be used as growth factors for breast tissue
engineering to encourage tissue induction and adipogenesis. Experiments to
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investigate the mechanism for the growth stimulation by linoleic acid and
arachidonic acid (20:4, ω-6) have focused on the eicosanoids.
An enzyme, Δ6-desaturase, catalyzes a reaction to produce gammalinolenic acid (18:3 n-6) from linoleic acid (128). Results reported in the literature
suggest that γ-linolenic acid inhibits mammary cancer cell growth (140).
Arachidonic acid (20:4, ω-6) may then be produced from γ-linoleic acid in reactions
catalyzed by enzymes elongase and Δ5-desaturase (128). The final step is the
production of the oxygenated derivative of arachidonic acid (20:4, ω-6), which is
associated with proliferation of both healthy and cancerous cells (129).
Studies in animal models have indicated a role for these eicosanoids,
notably prostaglandins, in experimental mammary carcinogenesis (141) (142) and
in cultures (143). This hypothesis was confirmed by Fulton when indomethacin,
an inhibitor of eicosanoid synthesis, was shown to mitigate the cell growth
stimulated by linoleic acid (18:2 ω-6) and arachidonic acid (20:4, ω-6) (144).

2.5 Lipid Peroxidation
Many studies have indicated that polyunsaturated fatty acids are lethal to
human cancer cells in concentrations not lethal to normal cells (145) (146) (147)
(148) (149). It is also observed that otherwise stimulatory fatty acids become
inhibitory at higher concentrations (110) (150). Begin and coworkers found a
correlation between the number of unsaturated bonds and cellular toxicity (104).
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Das and coworkers showed tumor cells supplemented with γ-linoleic acid
produced more free radicals than controls without γ-linoleic acid (151). It was also
shown that superoxide dismutase, an antioxidant, inhibited the γ-linoleic acidinduced cytotoxic effects in a dose-dependent manner (104). Begin and coworkers
further investigated this mechanism and discovered that Vitamin E, a powerful antioxidant, inhibited the killing of cancer cells by polyunsaturated acids such as
linoleic acid, arachidonic acid (20:4, ω-6), eicosapentaenoic acid, and
docosahexaenoic acid

(104).

These studies suggest lipid peroxidation and

reactive oxygen species may be the mechanism by which fatty acids have
cytotoxic effects.
It was once thought that eicosanoid production was related to lipid peroxide
formation; however, researchers have shown that eicosanoid synthesis
peroxidation, known as endoperoxide formation, does not affect lipid peroxidation.
This shows a distinctly different method of action than previously thought (104) . It
is worth noting that Rose dismissed these findings because Begin and coworkers
did not precomplex the fatty acids to albumin or dissolve the fatty acids in ethanol
(130) (152). Before testing fatty acids in-vitro culture, the fatty acids must be
complexed to bovine albumin or dissolved in ethanol for cellular uptake (130). The
mechanism for lipid peroxidation was later confirmed to be separate from
endoperoxidation.
Cells generate superoxide radicals through the conversion of oxygen to a
superoxide anion mediated by a plasma membrane-associated NADPH oxidase
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system (153). Researchers have shown stimulation of superoxide anion release
from neutrophils and macrophages by unsaturated fatty acids (154) (155) (156).
These superoxide radicals then form hydroxyl radicals in the presence of water
(154). Hydroxyl radicals react with unsaturated fatty acids in the cell membrane in
a self-propagating reaction to form lipid peroxides (157) (158). This mechanism
can be seen in Figure 6. This method of action was confirmed to be the mechanism
by which fatty acids are selectively toxic to cancerous cells by the addition of an
anti-oxidant which inhibited the observed anti-cancerous effect (104).

Figure 6: Self-Propagating Lipid Peroxidation Cycle.
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The mechanisms of increased reactive oxygen species formation in cancer
remain poorly understood; however, mitochondrial mutations which are frequently
observed in cancer patients, may play a role (157). Mitochondrial mutations in
cancerous cells are thought to generate superoxide radicals more frequently than
in wild type cells (159).
Among the common lipid peroxidation products are malondialdehyde, 4hydroxynonenal, and acrolein (160). Malondialdehyde is one of the most common
lipid peroxidation products, and is described as being specifically effective at
inhibiting tumor growth of breast and mammary carcinoma cells (161).
Malondialdehyde reacts with DNA replication leading to mutagenic genes and cell
death (162). Accumulation of malondialdehyde can also alter the membrane
permeability as well as impair fluidity of the membrane lipid bilayer (163).
Malondialdehyde is also commonly used as a biomarker for the quantification of
lipid peroxidation (164).
A recent study provides further evidence in support of the antitumor effect
of lipid peroxidation products in rodents. The researchers found that prevention of
mercapturic acid pathway-mediated elimination lipid peroxidation products
resulted in total remission of human cancer xenografts in nude mice (165). Fatty
acids, and their lipid peroxide derivatives,

may be used in combination with

anticancer agents such as tamoxifen and doxorubicin, which have been shown to
have an inhibitory effect on breast cancer cells which is greater than either
compound alone (166) (167).
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2.6 Eicosanoids
Eicosanoids are a class of cellular effectors derived from fatty acids. They
include

prostaglandins

(PGs),

prostacyclines,

thromboxanes

(TXs),

and

leukotrienes. Although some eicosanoids are produced by eicosapentaenoic acid,
the ones of concern are produced by arachidonic acid. The most common
arachidonic acid-derived eicosanoids are PGH2, PGE2, PGF2α, TXA2, and TXB2
(112). Arachidonic acid-derived eicosanoids produced by the cyclooxygenase and
lipoxygenase pathways are created in numerous types of immune cells and are
thought to regulate cytokine synthesis and inflammation (128).

2.6.1 Eicosanoids – Cellular Response
Eicosanoids have been linked to the growth of cells derived from human
endometrium (103), normal breast epithelial cells and fibroadenomas (129), and
breast cancer cells (139). They also have a role in adipogenesis (168) (169).
Prostanoids have been shown to upregulate PPARγs and may be the eicosanoids
responsible for adipogenesis seen by linoleic fatty acids (169).
Some studies have confirmed eicosanoid involvement in cellular growth
with the use of indomethacin, an inhibitor of eicosanoid synthesis. In vitro cultures
supplemented with indomethacin mitigated the growth effects seen by eicosanoids
from linoleic acid and arachidonic acid (139) (144). Eicosanoids normally control
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cellular growth through the regulation of inflammation pathways (169) . TXA2 and
PGE2 are vasodilators, which stimulate the collection of leukocytes and growth
factors in an area expressing the eicosanoids (169) .

2.6.2 Eicosanoids – Competitive Inhibition
Some fatty acids, like oleic acid and conjugated linoleic acid, will inhibit the
conversion of linoleic acid to gamma linoleic acid and, hence, inhibit its entry into
the eicosanoid biosynthetic pathways (139) (170) (171). CLAs are isomers of
linoleic acid and do not participate in the eicosanoid pathway. Due to their
structural similarities, CLAs may be competitors for the same enzymes, which
participate in the transformation of linoleic acid to arachidonic acid (20:4, ω-6)
(132). This yields an inverse relationship between conjugated linoleic acid
concentration and eicosanoid production.
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Figure 7: Method of Eicosanoid production. Information from Belury (128).
Martha Belury wrote a review of possible mechanisms of inhibition of
eicosanoids by conjugated linoleic acids where the enzyme cascade is shown in
Figure 7 (128). Belury states that CLA reduction of arachidonic acid-derived
eicosanoids has been explained by at least three theories. First, it is theorized that
CLA displaces arachidonic acid in phospholipids. In cultured keratinocytes, for
example, CLA reduced incorporation of C14 arachidonic acid (171). In addition,
dietary CLA displaced the arachidonic acid precursor, linoleic acid, in a doseresponsive manner in livers of mice fed various doses of CLA in some studies
(172). However this dose-responsive manner was not seen in other studies (128)
(173) (174).
A second explanation for the reduction of arachidonic acid-derived
eicosanoids by CLA is the inhibition of the constitutive enzyme cyclooxygenase,
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which could be inhibited at the level of mRNA, protein transcription, or protein
activity. An in vitro activity assay showed that CLA inhibited the rate of oxygenation
of arachidonic acid in the presence of cyclooxygenase (175). However, whether
CLA reduces the expression of cyclooxygenase is yet to be determined.
A third theory raises the possibility that CLA, or elongated and desaturated
products from CLA, may act as a substrate or antagonist for cyclooxygenase,
thereby reducing available enzymes for arachidonic acid. It seems unlikely that
conjugated-eicosatetarenoate (24:4) can act as a substrate for cyclooxygenase,
because cyclooxygenase requires the 1,4 methylene interruption to be farther from
the carboxyl end for efficient election extraction by prostaglandin synthase. More
likely, CLA may act antagonistically to inhibit the activity of cyclooxygenase (128)
.
2.7 Scaffolds
Mechanical properties of scaffolds are important to tissue engineering.
Preadipocytes, for example, are anchorage dependent cells and require growth
arrest for differentiation to occur (31) (36) (40) (176). It has been suggested that
scaffoldings with similar conditions as native conditions may perform better (177).
However, only one study has been able to show the success on a long-term (12
month) basis in rats (178). It is imperative for novel scaffolding to be created to
have in vivo efficacy as well as mechanical properties favorable to tissue
engineering.
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2.7.1 Scaffolding – Design Criteria
A proper scaffolding for breast tissue engineering must fulfill multiple design
criteria. Scaffolding for adipose tissue engineering has typically been designed for
restoration of tissue volume as opposed to restoration of tissue function. Therefore,
the scaffolds ideally restore the aesthetic function of the tissue by imparting a soft
smooth feel closely resembling that of natural tissue. The rigidity, or stiffness, of
scaffolds used for adipose tissue engineering is therefore one property that must
be considered (179) (180). The properties of a scaffold are largely determined by
the materials used in construction, the construction method, and any postconstruction treatments of the scaffold.
Beyond the aesthetics criterion, other concerns include mechanical
properties for cellular attachment (31) (40) (70) (40) (176) (181), pore size (182),
degradation profile (183), and bioactivity (184). Normal mammary tissue has been
characterized as rubber-like due to its almost incompressible nature (10) (185),
where the elastic modulus for mammary adipose tissue has been reported as 0.525 kPA (186) (187). Large pore size is important to allow the preadipocytes to
incorporate lipids and enlarge during differentiation. Pore size was found to be an
influencing factor in adipogenesis in several polymer sponges and non-woven
fibers size (182).
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2.6.2 Scaffolding – Materials
There are a wide variety of materials used for scaffolding. These include
decellularized animal tissues (75) (76) (77), as well as both synthetic and natural
polymers. In the broad field of tissue engineering the most widely used are porous
absorbable polymers, which include poly-L-lactide, polyglycolide, and copolymers
of the two (188) (189). However, due to the soft and malleable nature of adipose
tissue, it may be best to use materials which mimic this behavior as closely as
possible; hence the scaffold form is important.
There are cases where an untreated polymer has low cell affinity, but the
coated or treated polymer has high cell affinity. Polytetrafluoroethylene,
commercially known as Teflon®, is a polymer to which, if left untreated,
preadipocytes do not attach; however, human preadipocytes are able to proliferate
and differentiate into adipocytes on fibronectin-coated polytetrafluoroethylene in
vitro over a period of several days (181). Regardless, most of the recent focus in
adipose tissue engineering has been towards hydrogels rather than rigid polymer
matrixes.
Hydrogels are insoluble three-dimensional polymeric networks that absorb
and retain a significant amount of water. Currently, hydrogels are employed in
biomedicine for controlled drug release, soft tissue augmentation, cell separations,
and biosensing. The mechanical solute permeability, swelling, and hydrophilic
hydrophobic properties of a hydrogel are tuned by choice of monomers and
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hydrogel synthesis (190). Commonly used biomedical hydrogel materials are:
polyacrylamide (191), polyhydroxyethylmethacrylate (192), methacrylic acid (193),
methyl-methacrylate (193), maleic anhydride (193), poly(N-vinyl pyrolidone),
polyethylene glycol (194), polyethylene oxide (194), polyvinyl alcohol (195),
alginate, collagen, dextran (192) (196), hyaluronic acid (197), and chitosan (198)
(199) (200).
A large focus has been on the natural polysaccharides and proteoglycans
such as alginate, collagen, dextran, hyaluronic acid, and chitosan. These
hydrogels appear to have select promising characteristics for use specifically in
breast tissue regeneration. Studies have been conducted using calcium alginate
gels as well as hyaluronic acid gels, where the interaction of preadipocytes with
the gel material has been investigated (30) (38).
Commercial alginates are extracted from a few species of brown algae in
which alginate contributes to approximately 40% of the dry weight (201). Alginate
exists as a mixed gel of various divalent cations, such as Mg2+, Sr2+ and Ba2+,
found in seawater. This makes production of alginate hydrogels easy and
inexpensive, but because they are formed by a reversible reaction, the gels may
degrade far too quickly (202) (203).
Chitosan is a cationic polymer, and is the second most abundant polymer
in nature after cellulose (204). Chitin is the primary structural component of the
outer skeletons of crustaceans, and is found in many other species such as
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mollusks, insects, and fungi. The most commonly obtained form of chitosan is the
alpha chitosan, obtained from crab and shrimp shell wastes (204) (205). In
preparing chitosan, ground shells are deprotonated and demineralized by
sequential treatment with alkali and acid, after which the extracted chitin is
deacetylated to chitosan by alkaline hydrolysis at a high temperature. The
production of chitosan from these sources is inexpensive and easy. Chitosan is
fully soluble at pHs below 5, allowing unique techniques to form hydrogels from
this material. The polymer has been extensively studied for industrial applications
based on film and fiber formation, and the preparation and mechanical properties
of these forms have been reviewed previously (198) (199) (200) (206).
Hyaluronan, or hyaluronic acid, is clinically used in vascular surgery and
arthritis treatment (207). The high charge density and lack of crystallinity makes
the sulfated glycosaminoglycan (GAG) highly water soluble. Extensive
esterification of hyaluronan generates materials that form water insoluble films or
swellable gels (208). Ethyl and benzyl-esterified hyaluronan membranes have
demonstrated excellent healing responses and biodegradability in vivo. The fully
esterified membranes have in vivo lifetimes of several months, whereas the
partially esterified forms have been shown to degrade within a few weeks (197).
Hyaluronic acid has been shown to have anti-inflammatory effects (209).
Many materials are processed or adapted. Some polymers that are
chemically adapted, for example hyaluronan, may perform better if fully esterified
(197). Other chemical modifications include thiolated alginate (210), alginate
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chitosan complexes (211), thiolated chitosan (212), trimethylated chitosan (213),
carboxymethyl chitosan (214), and n-(2-hydroxyl) propyl-2-trimethyl ammonium
chitosan chloride (215).
Hydrogels can also incorporate degradable peptides into their polymeric
backbone to form hydrogels that are degraded by cell-secreted enzymes (183).
For instance, polyethylene glycol can be modified with the peptide sequence
leucine, glycine, proline, and alanine to form a polymer degradable by collagenase.
Preadipocytes have also been found to attach well to tyrosine, isoleucine, glycine,
serine, and arginine (216). Arginine, glycine, and aspartic can also be attached to
allow cells to adhere to the construct (217). In vitro studies demonstrated that
protein-modified hydrogels support cell attachment, adhesion, and proliferation
(218).

2.6.3 Scaffolds – Design Methods
Scaffolds can be produced from a number of different materials in a variety
of ways. Each production method is its own field of study. Scaffolds have been
made with the following design methods: woven fibers (219), extrusion (220),
freeze drying (221), phase separation (222), gas foaming (223), solid free form
fabrication (224), pH shift (225), solvent leaching (226), chemical crosslinking
(195), photo polymerization (195),

irradiative crosslinking (195), and thermal

gelation (206).
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Hydrogels are often produced by crosslinking, pH shift, or thermal gelation.
Other times, techniques are used to form porous hydrogels. This is seen in a study
where porous chitosan structures were formed by freezing and lyophilizing
chitosan acetic acid solution in suitable molds (227). In another study, a collagen
scaffold was constructed with uniform pore structure using a solvent casting
method followed by freeze-drying (228) (229).
Crosslinking is common to alginate gels and is generated by ionic crosslinks
between the carboxylic acid moieties and divalent cations such as Ca2+. Alginate
hydrogel beads can be prepared by depositing a solution of sodium alginate as
droplets into a crosslinking solution containing cations such as Ca2+ Sr2+or Ba2+
(203). Monovalent cations and Mg2+ ions do not induce gelation (202). The
exchange of sodium ions from the guluronic acids with the divalent cations, and
the flocculation of these guluronic groups achieve the crosslinking of the polymer
(203).
The pH shift is a method that allows the charge density of chitosan to form
insoluble ionic complexes with a wide variety of water-soluble anionic polymers.
Hydrogel formation has been documented with anionic polysaccharides such as
hyaluronic acid, alginate, and poly acrylic acid (230) (231). This endpoint is
commonly achieved by extruding a solution of chitosan, pH 5, as droplets into a
basic solution, pH 8, where the hydrogel will become water insoluble (198) (199)
(200). The addition of anionic polysaccharide will help stabilize the formation of
chitosan hydrogels but may complicate dissolving the extrusion solution (230).
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Thermal gelation is the process used for agarose, collagen, and gelatin
gels. These biomaterials are not very common in regenerative tissue engineering
but worth mentioning as they are very common in engineering tissue test systems.
Thermal gelation is a form of protein deformation and is normally irreversible in
vivo. Another irreversible chemical modification of polysaccharides, used to
produce hydrogels, is photopolymerization. A crosslinked hydrogel is achieved by
reacting a polysaccharide with methacrylic anhydride and adjusting the pH to basic
conditions (190). Laser exposure, with the addition of other agents will create
hydrogel microcapsules (190). This method allows the use of hyaluronan and
alginates without fear of the reversible crosslinks being removed.

2.8 Animal Models
The use of animal models is a necessity before any tissue engineered
construct can reach clinical studies. However, all animal experimentation must be
carried out ethically and in accordance with the guidelines for animal
experimentation and with the oversight of the institutional animal care and use
committee. Animal models have unique concerns to breast tissue engineering due
to the consideration of breast cancer. In breast tissue engineering, it is important
to consider whether or not an animal model has capacity for breast cancer.
Thought must be given to proper criteria for an animal model, including capacity
for breast cancer, method of breast cancer induction, and incubation times.
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2.7.1 Animal Models – Criteria
While numerous investigators have demonstrated select feasibility of small
animal models in adipose tissue engineering (232) (233) (234) (235), large animals
are not as commonly used. A large animal model with quantitative physiological
metrics is required in order to achieve the goal of restoring the human breast
mound after mastectomy (32) . Criteria for large animal models are detailed in
Table 9 (32) .
Table 9: Large Animal Adipose Tissue Engineering Criteria. From Patrick 2004
(32).

One such large animal to be used in breast tissue engineering is the
Yucatán micropig. Yucatán micropigs specifically offer the advantages of being
purebred, resulting in less in vivo variations, as well as being hairless, gentle, and
tractable. Preadipocytes have been successfully cultured from swine lineages,
allowing in vitro cultivation prior to implantation (236) (237)
Murine species have been used extensively, although they may not meet
all of Patrick’s suggested criteria (232) (233) (234) (235) (238). Murine species
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have the capacity for preadipocyte isolation as well as cancer induction (239)
(240). The induction of breast cancer is a desirable technique when evaluating the
ability of a tissue engineered implant to resist cancerous formation or infiltration.
Induction of breast cancer in vivo is more extensively studied in murine species;
therefore, it may be prudent to run animal studies with mice before studying
adipose engineered implants in Yucatán micropigs.

2.7.2 Animal Models – Induction of Breast Cancer
Tumorigenesis in human and laboratory animals is a complex and multistep
process (241). To evaluate a breast tissue engineered implant’s ability to resist the
recurrence of mammary tumors, animals must first have had a lumpectomy or
mastectomy. There appear to be three common modalities to accomplish the
formation of a primary tumor in animal models: chemical induction methods, tumor
transplantation methods, and genetic engineering methods.
Chemical induction of mammary carcinogenesis in murine species involves
the addition of chemical additives to either murine embryos, injection into local
tissue, or dietary induction. The most common chemical inducers used include
diethylnitrosamine

(232),

N-nitroso-N-methylurea

(233),

and

7,12

dimethylbenz(a)anthracene (242).
Transplantation of breast cancer tumors is a good way to simulate the
recurrence of breast cancer and, if transplanted in nude mice, can even test the
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response of primary human cancerous cells in vivo (234) (235). Tumor
transplantation is an attractive method because the experimental time may be
reduced drastically if the cancer tumor cultivation is removed. However,
transplantation in a nude mouse has the shortcomings of incorporating foreign
tumor cells that may not behave as they would in their native host tissue.
Another method for cancer induction is genetic engineering. Introduction of
the oncogenes Ras and Myc together into murine embryos will induce
tumorigenesis, but they must be introduced together (243) (244). Another
oncogene, HCCR-2, is known to be a human cervical cancer oncogene, but is also
overexpressed in various other human cancers. This oncogene is theorized to
function as a negative regulator of the p53 tumor suppressor (240). HCCR-2 forms
tumors that display the characteristics of a mammary epithelial carcinoma (239)
(240).

2.7.3 Animal Models – Implantation Time and Requirements
The time constraints of an animal model are affected by animal
development time, tumorigenesis time, and implantation time. Although the animal
development time may be avoided if the researcher purchases adult specimens
from a breeder, this limits the ability to use some chemical or genetic induction of
cancer techniques (232) (233). Although Patrick made persuasive arguments for
the use of Yucatan micropigs, they take 6 months to reach sexual maturity and 13
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months to reach adulthood (245) (246) (247). If using gene transfection, or
chemical induction, it may take up to 13 months before mastectomy and
implantation of the tissue engineered construct. This may not be a problem for late
stage research prior to human clinical trial, but may exclude testing emerging
concepts.
Using gene transfection or chemical induction with mice is less time
intensive. Mice reach sexual maturity in 4 weeks and adulthood in several months
(248). The use of HCCR-2 gene transfection has shown tumorigenesis in animals
at 4 months of age (239). This shorter development and tumorigenesis time may
allow less funded studies to perform in vivo experiments. The response of primary
human cancerous cells in vivo may be tested using adult nude mice (234) (235).
This method has the shortcoming of having foreign tumor cells that may not
behave the same as they would in their native host tissue.
.
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CHAPTER 3
EFFECTS OF LIPID PEROXIDATION BY LINOLEIC ACID
3.1 Introduction
Linoleic acid (18:2, ω-6) is the most common polyunsaturated ω-6 fatty acid
and is the parent of many other omega-6 acids. Kris-Etherton and coworkers
discovered that linoleic acid accounts for 85% of total fatty acids in American diets.
(113) This essential fatty acid is required by human cells to function and proliferate
but is not created by the body. Instead, humans typically ingest vegetable oils to
achieve the linoleic acid levels needed. Bagga and coworkers found that linoleic
acid concentrations differed, from 0.53 µM in healthy breast tissue to 0.66 µM in
cancerous breast tissue (108). Previous in-vitro studies have suggested increased
linoleic acid levels may promote cancer cell proliferation (131) (132). However,
most other fatty acids are thought to inhibit breast cancer cell proliferation (126)
(125). This discrepancy is partially explained by linoleic acid’s relation to
eicosanoids.
Cells convert linoleic acid to various eicosanoids through a series of
enzymes that has been previously described (128).

These eicosanoids are

associated with the proliferation of nearly all cells from the endometrium including
both healthy and cancerous mammary cells (152) (129).
Unsaturated fatty acids, such as linoleic acid, have been shown to induce
lipid peroxidation in cells (145). Mitochondrial mutations in cancerous cells are
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thought to generate superoxide radicals more frequently than in wild type cells
(159). These superoxide radicals then form hydroxyl radicals in the presence of
water (154). Hydroxyl radicals react with unsaturated fatty acids in the cell
membrane in a self-propagating reaction to form lipid peroxides (157) (158). This
method of action was confirmed to be the mechanism by which fatty acids are
selectively toxic to cancerous cells by the addition of an anti-oxidant which inhibited
the observed anti-cancerous effect (104).
Malondialdehyde is a common lipid peroxidation product and is described
as being specifically effective at inhibiting tumor growth of breast and mammary
carcinoma cells (161). Malondialdehyde reacts with DNA replication leading to
mutagenic genes and / or cell death (162).
Thus, it appears two types of metabolic pathways are relevant for fatty
acids, leading to the discrepancy between functions of linoleic acid and the rest of
the fatty acid families. One pathway involves cellular inhibition, where lipid
peroxidation leads to a build-up of radicals and lipid peroxides which are toxic to
cancerous cells, but not to normal cells (104). The second pathway involves
cellular stimulation, where eicosanoid production from linoleic acid may have a
growth factor-like effect on cellular metabolism (129). Because of the presence of
the two pathways, there may be a concentration or time point where linoleic acid
behaves like the rest of the polyunsaturated family. Work by Shultz and coworkers
(249) may have revealed this point. Although it was not the focus of their work,
their data indicates 35 µM and 70 µM of linoleic acid inhibited the proliferation of
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MCF7 cells after 8 and 12 days, while linoleic acid was stimulatory at 4 days. The
purpose of this collection of studies was to test a higher concentration of linoleic
acid, 100 µM, which may favor the lipid peroxide pathway and inhibit breast cancer
proliferation.

3.2 Materials and Methods
3.2.1 Reagents
High Glucose Dulbecco’s Modified Eagle’s Medium (DMEM) with Lglutamine was purchased from Atlanta Biologicals (Flowery Branch, GA). Fetal
bovine serum (FBS) was supplied by VWR (Radnor, PA). Anti-biotic-antimycotic,
fungizone, human recombinant insulin, and Vybrant® MTT Cell Proliferation Assay
Kits were all acquired from Life Technologies (Carlsbad, CA). Singlequots™
packages were obtained from Lonza (Basel, Switzerland). Lyophilized and gamma
sterilized linoleic acid-albumin and Lipid Peroxidation (MDA) Assay Kits were
supplied by Sigma-Aldrich Corp. (St. Louis, MO). Quant-iT™ PicoGreen® dsDNA
assay kits and alamarBlue® Cell Viability Assay kits were acquired from Invitrogen
(Grand Island, NY).

3.2.2 Cell Culture
Five cell lines were used across the collection of experiments. Human
epithelial breast cancer lines MCF7 (HTB-22™) and MDA-MB-231 (HTB-26™)
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cells were acquired from the ATCC (Manassas, VA). An induced murine tumor cell
line, 4T1 (CRL-2539™), designed to model late stage malignant human epithelial
breast cancer (250) was supplied by the ATCC. Two other cell lines were used as
controls. A noncancerous human epithelial breast tissue cell line MCF10A (CRL10317™) and primary subcutaneous pre-adipocytes, PCS-210-010™, were also
obtained from the ATCC.
Culture medium was DMEM supplemented with 10% FBS, 1% antibioticantimycotic, and 1% fungizone. Medium for the MCF7 cells had an additional 10
µg/mL human recombinant insulin. Medium for the MCF10A cells and PCS-210010 cells were additionally supplemented with a Singlequot™ kit which contained
human

endothelial

growth

factor,

insulin,

hydrocortisone,

gentamicin,

amphotericin, transferrin, triiodothyronine, and epinephrine.
Trypsinized cells were seeded at a density of 10,000 cells/ml in wells of
several flat, clear, tissue culture treated well plates from Greiner Bio-one (Monroe,
NC). Cell cultures were maintained at 37°C and 5% CO2 for the duration of the
experiments. Some samples were treated with various amounts of linoleic acid
bound to albumin reconstituted with PBS to a stock concentration of 2500 µM.
Samples were allowed to attach to culture plates for 3 days before the addition of
linoleic acid. Medium was refreshed every 2 days thereafter.
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3.2.3 Cell Viability Detection
The cellular metabolic activities were determined by either a resazurinbased assay or a formazan (MTT)-based assay. When resazurin was used, it was
applied for three hours to the culture before detection, by either using a method
solving for a system of Beer-Lambert’s law equations, or by fluorescent detection
described previously (251). When formazan was used, it was done so according
to previously published methods (252). Both methods were detected on a Biotek
Synergy™ Mx multiwell plate reader (Winooski, VT). When metabolic activity was
assessed over time, separate plates were used for each time point. Although
resazurin-based assays are considered nontoxic, work shown in Chapter 7 has
shown that resazurin is toxic to cancerous cells with extended exposure (80).

3.2.4 DNA Detection
Medium was removed and replaced with TE buffer following other assays.
The cell culture plates were subjected to being frozen (-20°C) and thawed (22°C)
three times to lyse the cells before the concentration of double stranded DNA was
detected by a PicoGreen® assay kit on a Synergy™ Mx multiwell plate reader
using previously described methods (253).

3.2.5 Lipid Peroxidation Detection
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The concentration of a product of lipid peroxidation, malondialdehyde, was
detected at the endpoint of 6 days of culture. A method involving a reaction of
malondialdehyde with thiobarbituic acid to form a colorimetric product proportional
to the malondialdehyde concentration was used. The colorimetric assay was
measured by the absorption of 532 nm light with a Biotek Synergy™ Mx multiwell
plate reader. This method has previously been described in more detail (254).

3.2.6 Statistical Analysis
JMP® 10 from SAS Institute (Cary, NC) was used to analyze the significance
of these data. Student’s t-tests and Tukey’s tests were used where a P-value of
less than 0.05 was considered significant. All data are reported as mean ± standard
deviation. Outliers more extreme than three times the interquartile range were
excluded, accounting for less than 5% of data.

3.3 Results
3.3.1 Evaluation of the MCF7 Cell Line
Linoleic acid was added to cultures of MCF7 and MCF10A cells at a
concentration of 100 µM for six days, then allowed to recover with just medium
alone for two more days. After eight days, six of which included treating the cell
lines with linoleic acid, the DNA concentration was measured for each cell line.
This revealed that the MCF7 cells cultured with linoleic acid had significantly
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reduced DNA concentration levels when compared to MCF7 cells cultured without
linoleic acid, containing only 25% ± 9.6% of the relative DNA concentration. The
linoleic acid treated MCF7 cells still contained 1400 ng/ml DNA. MCF10A cells
treated with linoleic acid also contained significantly less DNA, having only 58% ±
9.6% of the relative DNA concentration of untreated cell cultures. However, the
noncancerous MCF10A cells were significantly less affected than the cancerous
MCF7 cells. These data are shown in Figure 8.
A series of additional experiments was conducted to confirm these results.
The resulting DNA concentrations of the cancerous MCF7 cells were significantly
lower in all repeats and all time points. MCF10A cells were sometimes significantly
affected by the addition of linoleic acid, but always to a significantly less degree.
MCF7 cells treated with linoleic acid for eight days had 3.6% ± 5.3% of the relative
DNA concentration when compared to untreated controls, across all studies at
eight days in length. The average absolute DNA concentration for these treated
MCF7 cells was 70 ng/ml ± 101 ng/ml. This suggests the cell culture for MCF7
cells was not only inhibited but nearly completely removed by the addition of
linoleic acid.
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Figure 8: Deoxyribonucleic acid concentrations for cell cultures at various time
points and linoleic acid concentrations. Error bars represent ± one standard
deviation. Each individual study contained 9 repeats. Asterisks represent statistical
differences where a Student’s T-test was used (P-value < 0.05).
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Deoxyribonucleic acid concentrations gives insight into the proliferation and
survivability of cell cultures; however, a metabolic assay was performed to confirm
the results. Metabolic activity data for these cells are shown in Figure 9. Data from
eight days of culture with linoleic acid shows that MCF7 cells expressed only 7.4%
± 0.7% of the metabolic activity of control cells. Comparing data from six days
exposure to data from six days exposure plus two days in recovery media shows
a common effect observed in the laboratory. When the cells were exposed to the
linoleic acid, cells became stressed, raising the metabolic activity per cell. Having
the recovery period allowed the cells to return to a basal metabolic rate. Results
from this recovery time point are also included in Figure 9. One time point of
metabolic activity only has two repeats while DNA data was gathered from three
plates. The discrepancy is due to the failure of the assay plate reader, which
resulted in the loss of data.
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.
Figure 9: Metabolic activity for cell cultures at various time points and linoleic acid
concentrations. Error bars represent ± one standard deviation. Each individual
study contained 9 repeats. Asterisks represent statistical differences where a
Student’s T-test was used (P-value < 0.05).
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3.3.2 Evaluation Early Time Points
With 100 µM of linoleic acid, time points of 2, 4, 6, 8, and 10 days were
studied for their metabolic activity. Previous data from Shultz and researchers
(249) showed a 70 µM concentration of linoleic acid was beneficial to MCF7 cells
at the 2-day time point; however, these results were not observed here. Treatment
groups of 0 µM and 100 µM linoleic acid cultured with MCF7 cells were statistically
different on days 2, 4, 6, 8, and 10. These results, shown in Figure 10, indicate a
reduction of metabolic activity in cell cultures as early as two days when 100 µM
linoleic acid was used.
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Figure 10: Metabolic activity over time for cell cultures at various linoleic acid
concentrations. Error bars represent ± one standard deviation. Each individual
study contained 12 repeats. Asterisks represent statistical differences where a
Student’s T-test was used (P-value < 0.05).
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3.3.3 Evaluation of the 4T1 Cell Line
The effect of linoleic acid on 4T1 late stage metastatic breast cancer model
cells was also investigated. Results from two studies, for eight days with ten
repeats per study, revealed the reduction in 4T1 cell survivability through lower
DNA concentrations, shown in Figure 11, and metabolic activity shown in Figure
12.

Figure 11: Deoxyribonucleic acid concentrations of cell cultures at various time
points and linoleic acid levels. Error bars represent ± one standard deviation. Each
individual study contained 10 repeats. Letters represent statistical groupings
where a Tukey’s test was used (P-value < 0.05).
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Figure 12: Metabolic activity for cell cultures at various time points and linoleic acid
levels. Error bars represent ± one standard deviation. Each individual study
contained 10 repeats. Letters represent statistical groupings where a Tukey’s test
was used (P-value < 0.05).
There was a high variability in DNA concentrations for all samples.
However, it is clear that 25 µM linoleic acid had no consistent effect on cell lines,
while 100 µM linoleic acid once again showed a statistically significant reduction
of cancerous cell survivability after eight days of exposure. Metabolic activity for
the 4T1 cells cultured with 100 µM was found to be 4.2% ± 7.6% of the metabolic
activity of the control cells. This suggests the reduction of 4T1 metastatic cancer
cell survivability while the noncancerous mammary MCF10A cell lines were not
significantly affected.
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3.3.4 Evaluation of the MDA-MB-231 and PCS-210-010 Cell Lines
Another human mammary cancerous cell line, MDA-MB-231, was tested in
culture with linoleic acid. MDA-MB-231 cells frequently react differently to toxins
than MCF7 cells due to their mutant p53 gene (255). While MCF7 cells have a wild
type p53 gene (256), MDA-MB-231 cells express mutant p53 genes (257).
Primary subcutaneous preadipocytes were also tested with linoleic acid to
model the expected breast tissue environment in a post-lumpectomy patient along
with the MCF10A proliferative epithelial breast cell line. Five independent plates
were cultured for six days with two repeats per cell line. DNA results, shown in
Figure 13, reveal that MDA-MB-231 cells were statistically significantly affected by
the addition of 100 µM linoleic acid in all studies after six days. As observed with
4T1 cells, 25 µM linoleic acid was not consistently effective in any of the cell lines.
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Figure 13: Deoxyribonucleic acid concentrations of cell cultures at various time
points and linoleic acid levels. Error bars represent ± one standard deviation. Each
individual study contained 2 repeats. Letters represent statistical groupings where
a Tukey’s test was used (P-value < 0.05).
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3.3.5 Lipid Peroxidation
Lipid

peroxidation

was

indirectly

detected

by

monitoring

malondialdehyde levels. After six days of culture, cell cultures were reacted with
thiobarbituric acid and measured via a colorimetric assay. Results shown in Figure
14 indicate that MDA-MB-231 cells cultured with 100 µM linoleic acid had
statistically significant higher levels of malondialdehyde when compared to
controls. Since cancer cells cultured with linoleic acid have been shown here to
reduce the number of cells in culture, the malondialdehyde results are normalized
to DNA levels. However, results for 100 µM linoleic acid were still found to be
statistically significant for MDA-MB-231 cells before normalizing. Malondialdehyde
levels in MDA-MB-231 cells cultured with 100 µM linoleic acid were found to be
increased by 600% ± 220% when compared to cells cultured without linoleic acid.
Neither of the control cells used exhibited a detectable significant difference in
malondialdehyde concentrations when cultured with 100 µM linoleic acid for six
days.
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Figure 14: Malondialdehyde concentration levels of cell cultures at various time
points and linoleic acid levels. Error bars represent ± one standard deviation. Each
individual study contained 10 repeats. Letters represent statistical groupings
where a Tukey’s test was used (P-value < 0.05).

3.4 Conclusions
Over a collection of six experiments, cancerous cells cultured in 100 µM
linoleic acid constantly resulted in a statistically significant reduction in cell
survivability (P-value < 0.05). Cancerous cells tested included human breast
cancer cell lines MDA-MB-231 and MCF7 as well as the murine model 4T1 cell
line to simulate late stage metastatic human breast cancer. In all of the cases, 100
µM linoleic acid resulted in statistically significantly lower cell counts and metabolic
activity as early as two days and near complete removal of the cell lines by eight
days (P-value < 0.05).
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Control cell lines for the experiments included breast tissue cell line
MCF10A and primary preadipocytes PCS-210-010 cells, where linoleic acid
treatment had no significant effect. The noncancerous controls were statistically
less affected by the linoleic acid additives than the cancerous cell lines (P-value <
0.05).
Concentrations of 25 µM linoleic acid were also tested against cell cultures
but showed no consistent effect across experiments or cell types. The presence of
a lipid peroxidation product, malondialdehyde, was confirmed and found to be
significantly more concentrated in cancerous cell lines cultured with 100 µM linoleic
acid. The malondialdehyde concentration was found to be elevated by 600% ±
220% when compared to cells cultured without linoleic acid (P-value < 0.05). The
anti-cancerous, yet healthy tissue proliferative, effects of linoleic acid warrant
further study for their potential use in breast tissue engineering and repair.
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CHAPTER 4
THE POTENTIAL IN BREAST TISSUE ENGINEERING FOR THE
COMBINED EFFECTS OF LINOLEIC ACID AND TAMOXIFEN
4.1 Introduction
Polyunsaturated fatty acids have been shown to induce lipid peroxidation in
cells (145). Results from Chapter 3 indicate linoleic acid also produces lipid
peroxides in cancerous cells at a higher rate than healthy cells and may be a useful
additive for a lumpectomy targeted tissue engineering scaffolding considering its
relationship to the synthesis of the tissue growth eicosanoids. This increased lipid
peroxide concentration in cancerous cells is thought to be due to mitochondrial
mutations in cancerous cells which generate superoxide radicals more frequently
than in wild type cells (159). These superoxide radicals form hydroxyl radicals in
the presence of water (154) which react with unsaturated fatty acids in the cell
membrane in a self-propagating reaction to form lipid peroxides (157) (158).
Polyunsaturated fatty acids have been shown to work well in combination
with some chemotherapeutics agents such as doxorubicin and mitomycin C. The
combination of these peroxidizable fatty acids and reactive oxygen species
therapeutics has been shown to have an inhibitory effect on breast cancer cells
which is greater than either compound alone (166). Specifically, cancer cell viability
was recorded at 54% of controls levels with doxorubicin alone and at 21% with
doxorubicin and docosahexaenoic acid combined (22:6) (166). There was no
cellular toxicity observed when a non-peroxidizable fatty acid, oleic acid, or a non77

free radial generating therapeutic, mitoxantrone, was used (166). Free fatty acids
and lipid peroxidation are found in the cellular membrane (157) which is influenced
by diet. A correlation between doxorubicin effectiveness and the degree of
polyunsaturation in membranes has been observed in-vitro (258), while the
effectiveness of mitomycin C has been observed to be more effective in-vivo in
animals with human breast cancer tumors when given diets high in peroxidizable
fatty acids (259).
Tamoxifen is not known to induce lipid peroxidation, and its active
metabolite, 4-hydroxytamoxifen is believed to have a primary mechanism of action
through the inhibition of estrogen receptors (260). However, some research has
suggested a correlation between tamoxifen and changes in oxidative stress and
mitochondrial permeability transition pores (MPT) (261). These mitochondrial
changes may cause higher levels of superoxide radicals which may upregulate
lipid peroxidation thereby increasing cellular toxicity in ER+ cells. Tamoxifen is
commonly prescribed to post-lumpectomy patients (21) and would most likely be
included into any future post-lumpectomy tissue engineering scaffolding. The
relationship between high concentrations of linoleic acid and tamoxifen treatment
warrants investigation to determine the degree of interaction, if any is exists.
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4.2 Materials and Methods
4.2.1 Cell Culture
Lyophilized and gamma sterilized linoleic acid-albumin (Sigma-Aldrich
Corp., St. Louis, MO) was reconstituted with 7.4 pH phosphate buffered saline
(PBS) (Cellgro, Manassas, VA) and then added to medium to prepare a 100 µM
solution. Tamoxifen (Sigma-Aldrich Corp) was added to medium to create a 10 µM
solution. Medium for the cancer cells, i.e. the MCF7 cells (ATCC, Manassas, VA,
USA), was Dulbecco’s Modified Eagle’s Medium (DMEM) (ATCC) supplemented
with 10% fetal bovine serum (Cellgro), 1% antibiotic-antimycotic (Cellgro), 1%
fungizone (Cellgro), and 10 µg/mL insulin (Gibco, Grand Island, NY). The control
for the experiment was a non-tumorigenic mammary epithelial cell line, MCF10A
(ATCC). Medium for this cell line was DMEM supplemented with 10% fetal bovine
serum, and one Singlequots™ package (Lonza, Basel, Switzerland). A
Singlequot™ kit contains human endothelial growth factor, insulin, hydrocortisone,
gentamicin, amphotericin, transferrin, triiodothyronine, and epinephrine.
MCF7 and MCF10A cells were seeded at 20,000 cells/ml in each well of a
flat, clear, tissue culture treated 96-well plate (Greiner Bio-one, Monroe, NC). Forty
wells were seeded for each cell type. A volume of 200 µL of medium, specific to
the cell type, was added to each well and the cells were cultured for 72 hours at
37oC and 5% CO2. At the 72-hour time point, and every 48 hours thereafter, the
medium was refreshed. Conditions for each cell type, beginning at the 72-hour
time point, included supplemented medium, supplemented medium with
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tamoxifen, supplemented medium with linoleic acid, and supplemented medium
with linoleic acid and tamoxifen. The media with linoleic and/or tamoxifen
supplements were termed “treated” media.
This experimental design included ten sample wells and two acellular
controls per treatment condition. All samples were cultured in their respective
conditions for 6 days with media changes every 2 days. This experimental design
was repeated for a total of three individual experiments, each on a new 96-well
plate. An extended study was conducted on a single plate with nine samples and
two acellular controls per treatment conditions. Cells cultures for the extended
study were cultured for an additional 2 days in standard growth media after the 6
days of culture in treated media to get insight into the unstressed cell state.

4.2.3 Cell and Media Analyses
Assays were conducted on Day 6, or Day 8 of the extended study. At this
time, alamarBlue® Cell Viability Assay kit solution (Invitrogen, Grand Island, NY)
was added at 10% concentration to each well, including acellular wells. Samples
with alamarBlue® were cultured for another 3 hours, then the fluorescence was
read using a Synergy™ Mx multiwell plate reader (Biotek, Winooski, VT) at 530nm
excitation and 590nm emission. Deoxyribonucleic acid (DNA) and glucose levels
were also assessed in the samples, using a Quant-iT™ PicoGreen® dsDNA assay
kit (Invitrogen) and a YSI 2900 Biochemistry Analyzer (YSI Life Sciences, Yellow
Spring, OH) respectively. Medium was removed from all wells and stored at room
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temperature while 200μL 1x TE buffer (Invitrogen) was added to each well. The
plates, with 1xTE buffer in each sample well, were subjected to three cycles of
freeze-thaw from -20°C to 22°C, with 2 hours between cycles. The PicoGreen®
assay procedure was followed without deviation as listed in the product insert.
These data were converted to cell count from DNA concentration values, using a
control plate of known cell numbers (four plates per cell type, each plate containing
wells with 12 different concentrations of cells, i.e., 0, 2×103, 4×103, 6×103, 1×104,
1.4×104, 2×104, 4×104, 6×104, 1×105, 1.4×105, and 2×105 cells per well). The
medium was removed after the 2 days and analyzed using a YSI 2900
Biochemistry Analyzer to detect glucose and lactic acid levels. Two acellular
controls per sample condition were used to determine baseline glucose amounts.

4.2.4 Cell Staining and Imaging
Some wells were stained using a Quik-Dip® 3 Part Differential Stain
(Mercedes Medical, Sarasota, FL); subsequently, the medium was removed, and
the wells gently rinsed with PBS and filled with 200 µl methanol for 30 minutes to
fix the cells. After 30 minutes, the methanol was removed, and the wells were
gently rinsed with PBS and each well filled with 200 µl of the Quik-Dip eosinophilic
solution. The eosinophilic solution was left in contact with the cells for
approximately 30 seconds. After 30 seconds, the solution was removed, the wells
were gently rinsed with PBS several times, and each was filled with 200µl of the
Quik-Dip basophilic solution. After 30 seconds of cellular contact with the
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basophilic solution, the stain solution was removed. The cells were then rinsed
gently with PBS and imaged on a microscope. A Zeiss Axio Vert S100 inverted
microscope (Carl-Zeiss, Oberkochen, Germany) with a 32x objective was used to
view the stained cells under bright field light. A microscope-mounted 5 megapixels
AxioCam MRc 5 (Carl-Zeiss) was used to capture the images.

4.2.5 Statistical Analysis
Data from this experiment were analyzed with JMP® 10 (SAS Institute, Cary,
NC, USA) using a randomized complete block method. The standard model used
was yij = αi + βj + εij . The term βj was used to account for inter-experimental
variability, including variable days, assay calibrations, individual well plates, minute

differences in incubation times, and other effects associated with compiling
multiple experiments. The resulting system of equations was solved by finding the
least squares sum of the residuals, εij , with respect to a changing treatment

effect, αi , and blocking effect, βj . Data pieces which were more extreme than three

times the interquartile range were excluded as outliers. Outliers accounted for less
than 2% of all data points gathered. The variances between treatment groups were
found to be significantly different. Therefore, a two-tailed Student's heteroskedastic
statistical t-test was used for all comparisons, where a P-value less than 0.05 was
considered significant.
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4.3 Results
The DNA concentrations of the samples at time of lysing are shown in
Figure 15. Cells which were dead, but still intact, would contribute to these results.
These data give the most complete view of cell numbers as DNA concentration is
relatively constant within cells regardless of their stressed state. The results from
both the study and extended study suggest that the total DNA of cells in linoleic
acid-supplemented medium was lower and statistically different than the total DNA
of MCF7 cells in control media (P-value < 0.0001). The difference in total DNA of
MCF7 cells treated with tamoxifen alone and total DNA of those treated with the
combination of tamoxifen and linoleic acid was also determined to be statistically
significant (P-value < 0.0001). The total DNA of estrogen receptor-negative
MCF10A cells in tamoxifen-treated medium was statistically different from the total
DNA of MCF10A cells in untreated medium after 6 days, suggesting a possible
non-specific toxic effect. Although this may seem abnormal, tamoxifen has been
noted to have limited toxic effects in some healthy fibroblast cell lines (262).
MCF10A cells were isolated from a fibrocystic tumor and may have some
fibroblast-like traits.
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Figure 15: Deoxyribonucleic acid concentrations of cells treated with 10 µM
tamoxifen (t) and 100 µM linoleic acid (LA) against cancerous MCF7 cells (C) and
normal MCF10A cells (N). Extended time point includes six days treatment then
two days of rest, n ≥ 9. Error bars are ± σ. Letters (A,B,α,ß,γ,δ) represent statistical
groupings (P<0.05).
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The metabolic activity data, shown in Figure 16, should be viewed with a
critical eye. The plate reader uses an auto gain feature, leaving the units arbitrary,
relative to other studies. The fluorescence units should only be used to compare
data in these graphs alone. The 6-day time point study consisted of three individual
experimental runs, where auto gain would typically present a problem for data
analysis; however, auto gain variability was intentionally accounted for in the
blocking statistical method. MCF7 and MCF10A cells may undergo reduction
reactions with the resazurin in alamarBlue at differing rates. However,
comparisons between the cancerous and noncancerous cell data points should
not be made. In light of this caution, conclusions can still be drawn.
In the extended time point study, with 2 days for rest after treatment, linoleic
acid significantly lowered the metabolic activity of MCF7 cells when cultured with
or without tamoxifen supplements. Comparing the metabolic activity of MCF7 with
linoleic acid (C-LA) between days 6 and 8, shown in Figure 16, reveals the
importance of the recovery period in these studies. The DNA concentrations of the
C-LA samples in the 6-day study were significantly lower than the control; however,
the metabolic activity is significantly higher in the 6-day study for the C-LA
samples. This is due to the stressed state of the cells whereas in the extended
study, two days of recovery time after treatment allowed the cells to express their
basal metabolic rates.
The alamarBlue assay gives insight into the metabolic activity of the cell
cultures. This information is not necessarily related to toxicity but can be used, in
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conjunction with results from other assays, to infer either cell numbers or cell
activity. The PicoGreen assay (Figure 15) results clearly suggest the reduction of
cell number in linoleic acid-treated groups. Quik-Dip staining (Figure 17) also
shows the swollen cells from cellular uptake of fatty acids. These two sources of
data suggest the cell numbers in linoleic acid-treated MCF7 groups are fewer than
in the linoleic acid-free controls. However, the alamarBlue metabolic activity data
shows increased cellular activity in the 6-day study with no recovery time. With cell
counts known to be lower, this result implies either higher cellular activity per cell,
which could be caused by stress, or an artifact of the assay itself. The alamarBlue
assay functions by a reduction reaction of the fluorescent chemical with free
electrons at the end of the electron transport chain from metabolically active cells.
However, the assay may have been affected by electron radicals from lipid
peroxides, considering the high levels of linoleic acid and its potential in
undergoing lipid peroxidation, as shown in Chapter 3.
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Figure 16: Metabolic activity of cells treated with 10 µM tamoxifen (t) and 100 µM
linoleic acid (LA) against cancerous MCF7 cells (C) and normal MCF10A cells (N).
Extended time point includes six days treatment then two days of rest, n ≥ 9. Error
bars are ± σ. Letters (A,B,α,ß,γ,δ) represent statistical groupings (P<0.05).
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Figure 17: Histological stains of cell cultures growth with and without 100 µM
linoleic acid for 6 days. The cells are stained with Quik-Dip and photographed
using a 32x objective. Arrow A points to the size of the MCF10A control cell’s
extracellular matrix which is 21 µm in length. In comparison, arrow B points to the
size of the MCF10a cells treated with LA which has an extracellular matrix 61 µm
in length. Arrow C indicates the absorption of fatty acid into the MCF10a cells by
the black dots. MCF7 cells do not show these lipid accumulations. Arrow D shows
an area where the MCF7 cells are not in confluence.
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Values shown in Figure 18 are the control glucose levels minus the
experimental glucose levels.

The glucose results corroborate the PicoGreen

results and suggest that the proliferation of MCF7 cells in the presence of linoleic
acid and tamoxifen was severely inhibited. Glucose uptake of untreated MCF7
cells was higher than glucose uptake of cells treated with linoleic acid (P-value <

0.001 ) in both study formats.

Data from the extended time point suggests that the activity of the entire

population of MCF7s was completely curbed, as suggested by the almost
negligible levels of glucose uptake. This lack of glucose uptake suggests the
cellular samples have similar metabolic activity to the acellular controls. Glucose
uptake of MCF7 cells exposed to tamoxifen was greater than that of MCF7 cells
treated with tamoxifen and linoleic acid (P-value = 3 × 10−9 ). More importantly, the
untreated MCF7s had higher glucose uptake than that of cells treated with linoleic

acid (P-value = 1 × 10−14 ) . This result supports the hypothesis that higher
concentrations of linoleic acid may have favored the lipid peroxide pathway over
the eicosanoid pathway.
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Figure 18: Glucose uptake levels of cells treated with 10 µM tamoxifen (t) and 100
µM linoleic acid (LA) against cancerous MCF7 cells (C) and normal MCF10A cells
(N). Extended time point includes six days treatment then two days of rest, n ≥ 9.
Error bars are ± σ. Letters (A,B,α,ß,γ,δ) represent statistical groupings (P<0.05).
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4.4 Conclusions
While it has previously been shown that moderate levels of linoleic acid, 270 µM, promote in vitro mammary cancer cell proliferation, the results shown here
suggest that DNA levels of estrogen receptor-positive MCF7 breast cancer cells
were reduced when cultured in higher concentrations, 100 µM, of linoleic acid. The
noncancerous control cell line, MCF10A, did not experience this same antagonistic
effect. Results indicate that 100 µM linoleic acid was more effective at preventing
MCF7 cancerous proliferation than the breast cancer chemotherapeutic,
tamoxifen, alone. The combined effects of linoleic acid and tamoxifen was more
effective at lowering the cellular count of cancerous cells by day 8 than either of
the additives alone. This result is consistent with other fatty acids’ combining
effects with cancer therapeutics.
The implication of the potential action of linoleic acid/tamoxifen treatments
on cellular behavior is profound for the adipose tissue engineering community.
Linoleic acid, as well as other polyunsaturated (ω-6) fatty acids, has been shown
to encourage epithelial cell proliferation via the eicosanoid pathway (103). The
recognition of conditions that promote linoleic acid as a mammary cancer-inducing
compound versus those which promote it as an anti-cancer agent opens the
potential for breast tissue engineering scaffolding or treatments containing linoleic
acid. That is, combining linoleic acid-loaded scaffolds with tamoxifen may provide
a viable reconstructive approach for lumpectomy and mastectomy patients by
encouraging natural breast healing while limiting the ability of estrogen-receptor
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positive cancer cells to regrow. However, the limitations of an in-vitro study, which
examines one cell type without regard to stromal cells or in-situ conditions, when
compared to an in-vivo study must be recognized. Even with the limited scope and
implications for these observations, they still lend support to the use of linoleic acid
in tissue engineered constructs.
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CHAPTER 5
THE ADIPOGENIC PROPERTIES OF CONJUGATED
LINOLEIC ACIDS ON HUMAN STEM CELLS
5.1 Introduction.
Conjugated linoleic acids (CLA) are a group of polyunsaturated
octadecadienoic acid isomers which contain a pair of conjugated double bonds.
Conjugated linoleic acids are found in beef, lamb, and dairy-derived foods (114).
They have come to be studied in the fields of nutrition, animal veterinary sciences,
and cancer research. A mixture of CLA is also sold as a dietary supplement with
the intention of assisting in weight loss after receiving a Generally Regarded As
Safe (GRAS) rating by the FDA in 2008.
Conjugated linoleic acids have two biologically relevant isomers, cis 9, trans
11 octadecadienoic acid (c9t11 CLA), and trans 10, cis 12 octadecadienoic acid
(t10c12 CLA) (263) (264). The predominant isomer, c9t11 CLA, is also called
rumenic acid (134). Dietary supplements typically contain equal parts of c9t11 CLA
and t10c12 CLA, and human blood plasma levels have been found to be has high
as 180 µM CLA when taking these daily supplements (265).
Human endothelial cells treated with 50 µM of either c9t11 CLA or t10c12
CLA have been shown to release fewer eicosanoids (266) thereby limiting the
inflammation response caused by eicosanoids signaling molecules (267).
Conjugated linoleic acids have also been shown to reduce proliferation of

93

mammary tumor cells in vitro (109) (110) and in vivo (111) due to lipid peroxides
(104) (158). Unsaturated fatty acids, such as CLA, release superoxide anions
which form hydroxyl radicals (154) (268). These hydroxyl radicals create lipid
peroxides which are a reactive oxygen species and harm cancerous cells more
than normal cells (104).
However, much of the literature suggests CLA to be anti-adipogeneic,
particularly t10c12-CLA, via the downregulation of PPAR-γ (269) (270). Others
have reported osteoblastogenesis from human mesenchymal stem cells with
t10c12 CLA (271). It has also been shown that t10c12 CLA causes adipocyte
delipidation (272) (273) which appears to be caused by a rapid increase in
intercellular calcium (274). Concentrations of 6.25 µM to 50.0 µM t10c12 CLA have
been conclusive in their effects of downregulating adipogenesis.
Recently 12.5 µM of c9t11 CLA has been suggested to have an adipogenic
effect on human mesenchymal stem cells opposite that of t10c12 CLA (275).
Another study with 20 µM c9t11 CLA also observed a significant increase in
adipogenic differentiation of human mesenchymal stem cells (276). This
experiment sought to investigate the effect of a mixture of c9t11 CLA and t10c12
CLA used in cell culture. This could allow mixtures of CLA to be used as a
scaffolding additive for breast tissue engineers.
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5.2 Materials and Methods
5.2.1 Reagents
High Glucose Dulbecco’s Modified Eagle’s Medium (DMEM) with Lglutamine was purchased from Atlanta Biologicals (Flowery Branch, GA). A
mixture of c9t11 CLA and t10c12 CLA was purchased from Sigma-Aldrich (St.
Louis, MO). The CLA was dissolved in ethanol to 175 mg/ml. Dexamethasone, 3isobutyl-1-methylxanthine (IBMX), Dulbecco’s Phosphate Buffered Saline (PBS),
and Oil Red O were also ordered from Sigma. Fetal bovine serum (FBS) was
ordered from VWR (Radnor, PA). TRIzol® RNA isolation reagents, a high capacity
cDNA reverse transcription kit, anti-biotic-antimycotic, fungizone, and human
recombinant insulin were all ordered from Life Technologies (Carlsbad, CA).
QuantiTect SYBR® Green PCR Kit was ordered from Qiagen (Venlo,
Netherlands). Primers for RT-qPCR were ordered from Integrated DNA
Technologies (Coralville, IA).

5.2.2 Cell Culture
Human mesenchymal stem cells (HMSC) from bone marrow of passage 13
were acquired from ATCC (Manassas, VA). Culture medium for the HMSC cells
was DMEM supplemented with 10% FBS, 1% antibiotic-antimycotic, and 1%
fungizone. Trypsinized cells were seeded at a density of 10 000 cells/ml (21 000
cells/cm2) into each well of several flat, clear, tissue culture treated, 24-well plates
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from Greiner Bio-one (Monroe, NC). Cell cultures were maintained at 37°C and
5% CO2.
5.2.3 Experimental Groups
After 72 hours of culturing in growth media, some cell culture media were
supplemented with various concentrations of CLA ranging from 10 µM to 400 µM.
Another group of cell culture samples was given an adipogenic differentiation
control solution which consisted of 17µM insulin, 0.5µM dexamethasone, and 500
µM 3-isobutyl-1-methylxanthine (IBMX) (277). The final group of samples was to
be kept with unsupplemented growth media to serve as a control. Ethanol was
used to dissolve the CLA; therefore, an equal amount of 0.7 µL/mL (12 mM) was
added to all treatment groups. Media levels were 1.5 mL and were refreshed every
2 days.

5.2.4 Cell imaging
Some sample groups were imaged at the end of 6 days, while other groups
were imaged at the end of 12 days. A Carl-Zeiss Axio Vert S100 inverted
microscope (Oberkochen, Germany) was used with a phase contract microscopy
configuration. Images were taken with either a 32x objective or 10x objective while
a microscope-mounted 5 megapixels AxioCam MRc 5 (Carl-Zeiss) was used to
capture the images.
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5.2.5 Oil Red O Staining
Some wells were stained with Oil Red O. Designated wells were washed
with PBS, fixed with 10% formalin for 15 minutes, and then exposed to Oil red O
stain for 15 minutes. The stain was reconstituted to 5 mg/ml with isopropanol, then
diluted with 40% water before application to cell cultures. An Axio Vert S100
inverted microscope was used to capture the images under a 10x objective, and a
microscope-mounted 5 megapixels AxioCam MRc 5 was used to capture the
images.
5.2.6 Reverse Transcription Qualitative PCR
Some sample groups were lysed and RNA was isolated with TRIzol® after
12 days in culture. The isolated RNA was converted to cDNA with a high-capacity
cDNA reverse transcription kit. The cDNA and primers were then run with SYBR
green on a StepOnePlus™ thermocycler (Life technologies). Primers for
amplification are listed in Table 10 where Ribosomal 18S (18sRNA) serves as the
housekeeping gene (278).
Table 10: Sequences of primers used for reverse transcriptase quantitative PCR.
Primer assay IDs indicate primer sequences by Integrated DNA Technologies.

97

5.2.7 Statistical Analysis and Software
Data were repeated in triplicate across separate and independent plates.
Reverse transcription qualitative PCR (RT-qPCR) results were first analyzed by
StepOne v2.3 software, then JMP® 10 from SAS Institute (Cary, NC). Student’s ttest and an all pairwise Tukey’s comparison was used where a P-value of 0.05
was considered significant. All data are reported as mean ± standard deviation.
Images were captured in ProgRes® CapturePro 2.8.8 software from Jenoptik
(Jena, Germany).

5.3 Results
5.3.1 Concentration Array
A variety of CLA concentrations were added to medium conditions as
supplements to determine the most promising candidate to encourage
adipogenesis. Figure 19 shows the results from 6 days at the specified media
concentrations taken with a phase contrast microscopy technique. HMSC cells
with 0 µM CLA served as a control to compare the results of various CLA
concentrations. There did not appear to be any visual differences from 0 µM to 100
µM CLA supplementation. An apparent decrease in cell density was visible for cells
supplemented with 200 µM CLA, while cells with 300 µM CLA and 400 µM CLA
showed signs of apoptosis. A concentration of 100 µM CLA was chosen to
examine the mRNA adipogenic gene expression in a further study. The highest
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concentration without being toxic to the cells was chosen in order to have excess
c9t11 CLA. Previous literature has suggested 12.5 µM c9t11 CLA was sufficient to
encourage adipogenesis in HMSC (275). Thus a concentration far in excess of this
was chosen considering the mixture of CLA contained equal parts of c9t11 CLA
and t10c12 CLA.

Figure 19: Phase contrast images of HMSC cells grown with various amount of
c9t11 and t10c12 conjugated linoleic acids after 6 days of culture. Images were
taken with a 10x objective.
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5.3.2 Fatty Acid Absorption
A lipid specific stain was used to demonstrate the absorption of CLA into
the cells. Figure 20 shows the results of an Oil Red O Stain which was applied to
some of the samples after 12 days of culture. Phase contrast microscopy was used
in addition to the stain to aid in optical cellular definition. The images were
processed to have double the color saturation, allowing the red stain to be more
apparent. Figure 20 also shows how the fatty acid supplementation was successful
in cellular uptake. Conjugated linoleic acids are soluble in room temperature water
at up to 500 µM CLA, and therefore did not precipitate out of the solution due to
oversaturation.

Figure 20: Images of Oil Red O stained HMSC cells to demonstrate fatty acid
absorption. Images were taken with a 10x objective. Top row was altered to have
a higher color saturation. Lower row remained unaltered.
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5.3.3 Cell Morphology
Morphological changes could be seen between the 0 µM CLA control, 100
µM CLA treatment group, and adipogenic differentiation control groups after 12
days of culture, as shown in Figure 21. Between the 0 µM CLA control group and
the 100 µM CLA treatment group the cells appear less confluent, which is
important, as growth arrest is necessary for adipocyte differentiation (48) (279).
Preadipocytes expressing PPARy will also induce growth arrest (63). The cell
morphology changes from elongated fibroblast-like in nature to more adipocytic in
nature, which is swollen, and has reduced actin and tubulin expression, leading to
the less elongated shape (68). Comparing cells with 100 µM CLA to the adipogenic
control reveals how the morphology has changed to match more of a round,
swollen, omnidirectional shape.

Figure 21: Phase contrast images of HMSC cells treated with specified medium.
Morphological changes can be seen across treatment groups. Images were taken
with a 32x objective.
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5.3.4 Reverse Transcription Qualitative PCR
Gene expression levels for samples after 12 days in culture are shown in
Figure 22. Adipocyte protein 2 (aP2), also known as fatty acid binding protein 4
(FABP4), was clearly upregulated in cells cultured with CLA as well as in the
adipogenic cell control. Each mRNA expression is relative to the 0 µM CLA control
group for each gene and normalized by 18SRNA expression. AP2 mRNA
expression for cells with CLA is 40.0 ± 9.2 times higher than cells with no CLA and
is statistically significant with a P-value of 0.004. Expression of aP2 from cells
treated with the adipogenic control is 21.8 ± 6.4 times higher than expression from
cells with no additives and is statistically significant with a P-value of 0.01. CCAAT
enhancer-binding protein (C/EBP-α) mRNA expression was also statistically
different from the control with a P-value of less than 0.006.
Cells cultured with CLA had C/EBP- α mRNA expression levels 7.3 ± 1.4
times higher than controls. Cells cultured with the adipogenic control had
expression levels of C/EBP-α 5.2 ± 0.7 times higher than controls. Peroxisome
proliferator-activated receptor gamma (PPAR-γ) mRNA expression levels were
also statistically different from controls in both CLA treated and adipogenic control
treated samples with a P-valve less than 0.04.
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Figure 22: Reverse transcriptase qualitative PCR results show the relative mRNA
expression levels after treatment with a 100 µM mixture of c9t11 and t10c12
conjugated linoleic acids. HMSC cells grown with adipogenic differentiation
medium serve as one control while HMSC cells grown with unaltered growth
medium serve as another. Results are shown as mean ± SD, n = 3, P < 0.05, and
letters (A, B) represent statistical groups from a pairwise Tukey's test.
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5.4 Conclusion
Human mesenchymal stem cells were cultured with a mixture of conjugated
linoleic acid to test for adipogenic properties. Concentrations ranged from 0 µM to
400 µM where concentrations above 200 µM showed visual signs of cellular
toxicity when supplemented in an in vitro culture for 6 days. The mixture of
conjugated linoleic acids at 100 µM concentration was able to upregulate aP2,
C/EBP-α, and PPAR-γ mRNA expressions above control levels in human
mesenchymal stem cells when supplemented for 12 days (P-value < 0.05). These
results supplement CLA’s known anti-cancerous properties though lipid
peroxidation and CLA’s ability to mitigate inflammation though eicosanoid
antagonism. A mixture of c9t11 and t10c12 conjugated linoleic acids could be a
useful scaffolding additive for breast tissue engineers.
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CHAPTER 6
THE CREATION OF BILAYERED HYDROGEL BEADS
6.1 Introduction
It is estimated that over 230,000 women will be diagnosed with breast
cancer in 2014 in the United States (1). Once a person has breast cancer, the
current model for treating cancerous breast tissue is excision of cancerous areas,
then radiotherapy (2). The majority (66.4%) of women with breast cancer will
receive a lumpectomy (5), and a growing percentage of women (37.8%) received
an implant immediately after tumor removal regardless of radiotherapy treatment
decisions. (6)
These lumpectomy void fillers include silicone implants; however, these do
not aid in the removal or prevention of cancerous recurrence. Specifically, silicone
implants may reduce the effectiveness of radiation treatments and delay detection
of dorsal cancer reoccurrence (7). One study found 15% of women with immediate
breast reconstruction had early complications due to the silicone implant. The most
common (21%) of complications was capsular contracture. The study found a
correlation between irradiation with silicone implants and increased complications
(7). A natural or tissue engineered construct should increase the efficacy of
radiotherapy and reduce the long-term number of patients with a cancerous
recurrence.
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Alternatives, such as musculocutaneous flaps, transverse rectus abdominis
muscle, and latissimus dorsi flaps, have been used as reconstructive materials (7)
(8). However, these are better suited for the larger voids created by mastectomy
than lumpectomies. Autologous implants do not help solve the 10-year 20% rate
of breast cancer reoccurrence either (4). Additionally, autologous adipose tissue
transplants may induce micro deposits of serum calcium from fat resorption that
may obscure mammography and interfere with tumor detection (9). The tissue
engineering field may offer some other options for these cancer survivors.
Adipose tissue engineering provides an opportunity to combat these
limitations through the development of biomaterials, which can successfully house
progenitor cells for both adipose differentiation as well as a scaffold that will exist
and maintain the structural shape and size throughout remodeling. This scaffolding
should not limit tumor detection or radiotherapy efficacy. Previous work done by
our group demonstrated the potential of a chitosan-gelatin hydrogel bead to
successfully provide such a platform for adipogenic growth (280). However,
advances have been made towards the creation of better improving this
technology with the inclusion of a bilayer on the hydrogel.
Other researchers have previously described a flat hydrogel bilayered
scaffolding with chitosan and gelatin (281); however, this work seeks to develop a
novel production technique to form a round hydrogel bilayered scaffolding which
may incorporate growth factors and chemotherapeutics in the production.
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This work investigated the methodology and characterization of our
bilayered hydrogel bead as a potential scaffold host for progenitor cells. Physical
characterization of the beads were conducted by histological analysis and
preliminary efforts into understanding hydrophobic compound elution. In vitro cell
culture was used to evaluate cell adherence, proliferation, and metabolic activity
of progenitor cells that are the basis of adipogenic tissue engineering.

6.2 Materials and Methods
6.2.1 Polymer Solution Preparation
Preparation of each of the three polymer solutions was completed
individually. A 1% v/v acetic acid solution was prepared by mixing 1 mL glacial
acetic acid (Fisher Chemicals, Fair Lawn, NJ) in 100 ml of Millipore Milli-Q ultrapure
deionized water. A 3% w/v chitosan solution was prepared by dissolving 3 g of
chitosan (100,000-300,000 MW, Deacetylation Degree >90%; Acros Organics
Scientfic, Morris Plains, NJ) in 100 mL of 1% v/v acetic acid, stirring at low heat
(~40°C) until completely dissolved (~3 hours). A 1% wt/v hyaluronic acid solution
was prepared by dissolving 100 mg of recombinant hyaluronic acid sodium salt
(Fluka, St. Louis, MO) in 10 mL of ultrapure deionized water. Lastly, a 3% w/v
gelatin solution was prepared by dissolving 300 mg of gelatin (Type A from porcine
skin; Sigma-Aldrich, St. Louis, MO) in 10 ml of ultrapure deionized water, heated
to 40°C in a water bath. A 0.5N solution of sodium hydroxide (NaOH) was prepared
by dissolving 10 g NaOH (Fisher Chemicals) in 500 ml ultrapure deionized water.
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6.2.2 Hydrogel Construction
The chitosan hydrogel beads were created using a pH shift gelation method
and a Var V1 electrostatic bead generator (Nisco Engineering, Zürich, CH). Once
the three polymers were individually dissolved, these solutions were mixed in a
16:1:2 ratio (chitosan:hyaluronan:gelatin). Mixing the solutions creates a final
solution with concentrations of 2.6wt% chitosan, 0.02wt% hyaluronan, and
0.33wt% gelatin. The resulting solution was mixed thoroughly and sonicated in a
water bath for 5 minutes. The bubble free solution suspension was then placed in
a 20cc syringe (Becton Dickinson, Franklin Lakes, NJ) that was secured to a
syringe pump (kdScientific, New Hope, PA) set to eject solution at 10 mL/hr. The
solution was dripped into the electrostatic bead generator with a voltage of 4.2kV
and a 2 cm drop height. This distance of needle above the NaOH solution was kept
constant by filling the collection dish completely with NaOH solution, allowing
added volume by the polymer drip to displace an equal volume as overflow. As
the beads dripped from a 19-gauge needle, they were collected in a 0.5N NaOH
stirred gelation bath, where the beads gelled and retained their droplet shape. This
process is shown in Figure 23. Uniform beads of only 3% w/v chitosan solution
were subsequently made under the same electrostatic bead generation procedure.
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Figure 23: Electrostatic bead generation conditions where the solution was
dissolved in an acid and dripped into a basic gelling solution.
After the multi-polymer beads formed in the NaOH bath, they were removed
and placed in a -20°C freezer to set the denatured gelatin. The hydrogels, in NaOH
solution, were in the freezer for 30 minutes, which is short enough to not observe
any solution freezing. The control uniform beads were removed and neutralized by
serial washings with Phosphate Buffered Saline (PBS; Sigma). The creation of a
second layer on the hydrogels required an acid washing step. The hydrogels
designated to become bilayered were in 0.5N NaOH solution. About 200 µL 98%
lactic acid was added to the solution containing the hydrogels which was
approximately 2 ml of 0.5N NaOH after shaking vigorously. The pH was raised with
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5N NaOH after 30 seconds in an acidic condition. The hydrogel beads were then
serially washed with PBS and stored in a 4°C refrigerator until use. A graphical
depiction of the acid wash is shown in Figure 24.

Figure 24: Acid rinsing procedure to partially remove chitosan from the outer layer
creating a bilayer effect.

6.2.3 Sectioning and Staining
The beads were sectioned using a cryosectioning technique specific for
hydrogel beads (282). The hydrogel solutions were dehydrated by dilutions with
sucrose then replaced by OCT compound as shown in Table 11. The volume of
hydrogels used was such that 1mL of solution was sufficient have them fully
submerged.
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Table 11: Hydrogel dehydration steps adapted from Yang 2007 (282).

The frozen hydrogels were sectioned into 5 µm slices with a Thermo
Scientific cryostat (Waltham, MA). Once attached to microscope slides, the
sections were soaked in water for 10 minutes to remove the OCT compound. The
slides were soaked in aniline blue stain for 5 minutes after the OCT removal.

6.2.4 Cell Culture
D1 cells, murine bone marrow stromal stem cells, were acquired from ATCC
(CRL-12424, Manassas, VA) and maintained in High Glucose Dulbecco’s Modified
Eagle’s Medium with L-glutamine (DMEM; Atlanta Biologicals, Norcross, GA)
supplemented with 10% fetal bovine serum (FBS; VWR, Radnor, PA), 1% anti-
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biotic/antimycotic (Life Technologies, Carlsbad, CA), and 1% fungizone (Life
Technologies). Cells were used for this experiment at passage 21.
Ten hydrogel beads, both uniform and bilayered, were placed in wells of a
low attachment, 6-well plate (Corning, Manassas, VA). D1 cells were seeded at a
density of 2000 cells/hydrogel bead and placed on an orbital shaker for a more
uniform cell attachment. Cell cultures were maintained at 37°C and 5% CO2 with
medium replaced every two days.

6.2.5 Cellular and Metabolic Analyses
After 14 days of culture, the medium was removed from all wells and
glucose levels were detected using a YSI 2900 Biochemistry Analyzer (Yellow
Spring, OH). The hydrogels with cells attached were transferred to a new well plate
and filled with 1 mL Tris-EDTA buffer (Invitrogen, Carlsbad, CA) in each well. The
cells and hydrogels were lysed by sonication. Lysates were then used to detect
the double stranded deoxyribonucleic acid (dsDNA) concentration using the
Quant-iT™ PicoGreen® dsDNA assay kit (Invitrogen) and a Biotek Synergy™ Mx
multiwell plate reader (Winooski, VT) according to manufacturer protocol.

6.2.6 Cell Imaging
Samples were imaged at the end of 14 days of culture. A Carl-Zeiss Axio
Vert S100 inverted microscope (Oberkochen, Germany) was used with a phase
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contract microscopy configuration. Images were taken with a 10x objective while a
microscope-mounted 5 megapixels AxioCam MRc 5 (Carl-Zeiss) was used to
capture the images.

6.2.7 Elution Study and Gas Chromatography
Chitosan, hyaluronic acid, and gelatin hydrogel beads were created with
400 µM conjugated linoleic acid (CLA). The dissolved polymer mixtures, basic
gelling solution, and storing solution, were all modified to have 400 µM CLA for the
purpose of both inclusion of CLA within the beads as well as minimizing elution
during storage. Half of the hydrogels were treated to become bilayered, while the
other half severed as uniform hydrogels controls. A 12-well plate was used to hold
1 ml of beads (~20 beads) in each well. Six wells were dedicated to single-layered
beads, and six wells to bilayered beads. After 3 rinses of PBS with CLA rinses, 1
ml of medium was added to each well. At time points of 1, 3, 8, 14, 35, and 70 days
the medium was removed and analyzed by gas chromatography. Briefly, fatty
acids were separated by a chloroform, water, and methanol liquid-liquid extraction.
The fatty acids were then transesterified with sodium methoxide and methanolic
HCL. The methylated fatty acids were separated by another liquid-liquid extraction.
The samples were run finally on an Agilent technologies 7890a GC system with a
100 m column (Santa Clara, CA). Controls included a known concentration control
of CLA and an internal standard of nonadecenoic acid.
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6.2.8 Statistical Analysis and Software
Data were analyzed by ChemStation® from Agilent Technologies and JMP®
10 from SAS Institute (Cary, NC). Images were captured in ProgRes® CapturePro
2.8.8 software from Jenoptik (Jena, Germany). Student’s t-test was used to
compare uniform beads and bilayered beads, where a P-value of 0.05 was
considered significant. All data are reported as mean ± standard deviation.

6.3 Results
6.3.1 Bilayer Hydrogel Imaging
The creation of gelatin, hyaluronic acid, and chitosan hydrogel beads was
found to be possible with the use of an electrostatic bead generator and a pH
shifting technique. The hydrogel beads could be treated with an acid wash and
found to have distinctive second layers as seen in Figure 25A. The hydrogels were
created successfully and repetitively across three separate batches with diameters
of 1.65 mm ± 0.25 mm for bilayered beads, and 2.86 mm ± 0.37 mm for uniformlayered beads. These sizes are dependent upon the flow rate of the syringe pump,
voltage of the electrostatic generator, needle gauge, and height of needle from
gelling bath, and therefore, can be easily altered. The acid treated beads, which
became bilayered, were approximately half (58% ± 5%) the diameter of the
untreated hydrogels.
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Figure 25: Image A shows an acid treated hydrogel on the left with its clear outside
layer and a uniform bead to the right. Image B shows a uniform bead out of focus
demonstrating the effects of spherical aberrations when the object is focused
differently.
The uniform hydrogel shown in Figure 25B shows the effects of a spherical
aberration. To exclude the possibility of this effect giving the illusion of a bilayer,
beads were sectioned to confirm the presence of the second layer. A unique
hydrogel specific cryosectioning technique (282) was used to section the beads,
while aniline blue was used to visualize the sections. Figure 26 shows the 5 µm
thick sections and clearly shows the presence of a second layer on the acid-treated
hydrogel beads. The outer layer is likely shriveled due to the dehydration effect on
the hydrogel through the cryosectioning process.
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Figure 26: Sectioned and stained hydrogels stained with aniline blue. A shows a
uniform hydrogel at 10x. B shows the internal pattern of stain under 32x. C shows
a sectioned bilayered hydrogel under 10x. D shows a sectioned bilayered hydrogel
under 32x.
6.3.2 Cell Growth Studies
Murine stromal stem cells were grown on the hydrogel bead scaffoldings for
14 days. The bilayered hydrogels allowed for the migration of cells through the
outer layer and attachment at the boundary between the layers. This effect can be
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observed in Figure 27. Cell attachment is visible only on the surface of the uniform
hydrogel beads shown Figure 27D.

Figure 27: Cell growth images after 14 days of culture. A, B, and C show cells
growing between the hydrogel layers. D shows a uniform hydrogel beads cell
growth
The media, which was in contact with the cell cultures from day 12 to day
14, were extracted, and their glucose levels measured. Figure 28 shows the results
of this assay. Cell culture wells with bilayered beads had glucose levels of 3954
mg/mL ± 221 mg/mL while cell cultures on uniform beads had a significantly lower
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glucose concentration of 3277 mg/mL ± 63 mg/mL. Data were repeated in
triplicate. These lower glucose values imply there were either more cells on the
bilayered hydrogel or more active cells.

Figure 28: DNA concentration and glucoses uptake levels in samples after 14 days
of culture with murine bone marrow stromal cells. Where asterisks indicate
statistical significance (P-value < 0.05) Sample number of n=3 for each group.
Error bars represent ± σ.
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The cell lysates after 14 days of culture were analyzed for DNA
concentration to obtain insight into the cell numbers. These results can also be
seen in Figure 28. Cell culture wells with bilayered beads had DNA concentrations
values of 51.91 ng ± 9.80 ng while cell cultures on uniform beads had significantly
lower DNA concentrations of 22.43 ng ± 53.2 ng. Data were repeated in triplicate.
This implies the bilayered hydrogels allow for more cell growth, which is supported
by the glucose measurements.

6.3.3 Elution Study
An elution study was performed to evaluate the potential for the bilayered
hydrogel beads to be loaded with, and elute, hydrophobic drugs or materials.
Hydrogel beads loaded with a mixture of conjugated linoleic acids were placed in
physiological in vitro conditions for up to 70 days. Periodically the medium would
be removed and replaced while the removed medium was tested for conjugated
linoleic acids by gas chromatography. Figure 29 shows the results of this study.
Medium taken from time points after 3 days did not contain detectable
amounts of conjugated linoleic acids. The gas chromatography was able to detect
conjugated linoleic acids as low as 625 ppb. The medium, which had been in
contact with the hydrogel beads for 24 hours, showed 363 nmoles ± 73 nmoles of
CLA for bilayered beads, and 383 nmoles ± 91 nmoles of CLA for uniform layered
beads. The media in contact with the hydrogel beads from day 1 to day 3 were
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found to have 91 nmoles ± 28 nmoles for bilayered beads and 92 nmoles ± 40
nmoles for uniform beads. These results are similar and show a significant amount
of variability.

Figure 29: Gas chromatography boxplot results for the conjugated linoleic acid
elution study. Sample number of n=6 for each group.
The variability shows a similar distribution of values for both bilayered
hydrogels and uniform layered hydrogels with no outliers. The bilayered hydrogels
released 95.1% ± 30.4% the amount of conjugated linoleic acids as the uniform
hydrogel controls after 24 hours at a 95% confidence level.
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6.3.4 Discussion
A hydrogel bead made of the three polymers of chitosan, hyaluronan, and
gelatin was chosen to combine the benefits of each polymer in tissue engineering.
Chitosan hydrogel beads have shown potential in both tissue scaffolding (283) and
drug delivery (284). Chitosan is a cationic polymer, and is the second most
abundant polymer in nature after cellulose (205). Advantageous characteristics of
chitosan are bioresorption through degradation by human enzymes allowing for
scaffolding remodeling in in-vivo settings (285), as well as hemostatic properties
demonstrated in its use in commercially available wound dressings (286). Chitosan
is fully soluble at pH values below 6, allowing dissolved solutions of chitosan to be
dripped into higher pH solutions to cause gelation (287)
Hyaluronan, or hyaluronic acid, is an anionic glycosaminoglycan (GAG)
which is commonly used in vascular surgery and arthritis treatment (288). The
addition of an anionic polysaccharide has been shown to help stabilize the
formation of chitosan hydrogels, but may complicate dissolving the mixed solution
(231). Hyaluronic acid has been shown to have anti-inflammatory effects (197).
Another bioresorbable polymer, gelatin, is denatured the form of collagen and has
been shown to work well in combination with chitosan (289). Gelatin gels by
thermal gelation. A hydrogel with a combination of these three compounds may
have allowed for the stability of anionic, cationic interactions as well as
advantageous thermal gelation properties.
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The hydrogel beads made of chitosan, hyaluronan, and gelatin had
improved stability from the anionic and cationic interactions of the chitosan and
hyaluronan. However, chitosan is affected by the acid wash while gelatin is not.
The acid wash removes a small amount of chitosan while the hyaluronan and
gelatin remain. When samples were created without gelatin, the hyaluronan would
remain on a pseudo-bilayer but would slough off when exposed to small shear
forces. Hyaluronan was included to the mixture to have the desirable cell culture;
however, other anionic polymers might be substituted to have other targeted
effects.
Conjugated linoleic acids were included because they have also been
shown to reduce proliferation of mammary tumor cells in-vitro (109) (110) and invivo (111). A mixture of the two most common isomers has also been shown to
upregulate adipogenic markers

in Chapter 5. The CLA elution study was

performed to test the hypothesis that the bilayer would retard the elution of
conjugated linoleic acids allowing the hydrogels to retain an anti-cancerous and
adipogenic property. The results demonstrated conjugated linoleic acids were
released up to 3 days after the simulated implantation of the hydrogels but the
bilayer made no significant difference. However, if another anionic polymer were
used in place of the hyaluronan these properties may change.
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6.4 Conclusions
Material development within the field of tissue engineering is critical to
provide a platform to modulate proper cell functionality in the desired environment.
Naturally derived polymers have elicited extensive research as potential
biodegradable materials for scaffold creation. In this work, chitosan, hyaluronan,
and gelatin were formed into spherical hydrogel beads with a diameter of 2.86 mm
± 0.37 mm using an electrostatic bead generator and a pH solubility technique.
The hydrogel beads could then be treated with an acid wash for 30 seconds, which
resulted in a decrease in size to 1.65 mm ± 0.25 mm with a distinct bilayer. The
presence of a second layer was confirmed by a unique sectioning method for
hydrogels.
Cell attachment and proliferation were tested using murine mesenchymal
stem cells. The cells migrated through the outer layer and proliferated on the
boundary between the two layers of the bilayered hydrogel. After 14 days of culture
with stem cells, the bilayered hydrogels were found to have significantly higher
concentrations of DNA when compared to the uniform hydrogels (P-value < 0.05),
as well as lower media glucose levels (P-value < 0.05). To evaluate the bead’s
potential as a composite and delivery scaffold, elution rates of conjugated linoleic
acid from bilayered hydrogels were tested, but not found to be significantly different
(P-value > 0.05) from the elution rate of uniform hydrogel beads after a 24-hour
time point. This novel bioresorbable bilayered hydrogel design technique allows
for cells to be cultured while being protected from shear stresses.
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CHAPTER 7
TEST METHOD INNOVATION
7.1 Microplate Reader Sterile Technique
7.1.1 Introduction
Spectrophotometry is quantitative measurement of a solution’s colorimetric
absorbance, or fluorescent properties, in the electromagnetic spectrum (290). In
tissue engineering, spectrophotometry can be used to detect a wide variety of
colorimetric assays including dsDNA, triglyceride, metabolic activity, and lipid
peroxide assays. Traditionally, spectrophotometers operated by having a light
source pass through a sample at a specific wavelength, detecting the resulting light
on the distant side of the sample with a photo sensor, and calculating the percent
transmittance in relation to Beer’s law (291). However, modern plate readers may
have the sensor and emitter on the same side of the sample and measure
reflectivity or backscatter. The BioTek Mx used in these experiments uses only a
top probe.
Many cell culture assays require the sample to be incubated at 37°C prior
to detection by the spectrophotometer. However, spectrophotometers are typically
operated at room temperature. This temperature change causes condensation to
form on the top of the multiwell plates. Plate readers with bottom probes could
simply read from the bottom of the plate without interference, but plate readers
with top probes have interference introduced by the condensation. The top cover
could be removed from the cell culture plates; however, this is not feasible if the
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cell cultures are to be used later and need to be kept sterile. An alternative method
for measuring colorimetric and fluorescence is needed in order to allow the sterile
use of colorimetric assays.

7.1.2 Materials and Methods
An acellular 96 well plate was filled uniformly with a 10% resazurin solution,
sold as alamarBlue® (Invitrogen, Grand Island, NY), and 200 µL Dulbecco’s
Modified Eagle’s Medium (ATCC, Manassas, VA). A SynergyMX multi-well plate
reader (Biotek,Winooski,VT) spectrophotometer was programmed to the
procedure shown in Figure 30.

Figure 30: Method configuration in Gen 5 SynergyMX programming.
The plate was placed in a 37°C incubator for 30 minutes before analysis by
the spectrophotometer. The plate was measured using three methods. One
method used the 37°C set point for the spectrophotometer with the top cover lid
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on, one was at room temperature with the top cover lid on, and the final was at
room temperature with top cover lid off.

7.1.3 Results and Conclusion
The uniformly filled 96 well plate in the 37°C incubator was removed and
run on the spectrophotometer with as little delay as was possible. However,
significant condensation was observed within a short time frame. The 10%
resazurin solution was measured and the results are shown in Figure 31. The
absorbance reading at 570 λ was normalized to the average of all samples.
Microsoft Excel’s conditional formatting was used to show the differences by color.
The same plate was then measured with its top cover lid off after the same amount
of time in the 37°C incubator. The results for this method are shown in Figure 32.

Figure 31: Top on method were a uniform 96 well plate was read with its top on
showing the effects of condensation from removal from 37°C.
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Figure 32: Top off method where a uniform 96 well plate was read with its top off
showing the typical distribution of variance amongst a uniform sample.
These results suggest that if the top can be removed, then it should be
removed. However, certain experimental conditions mandate that the plate remain
sterile. To accomplish this, a methodology was developed in the Gen 5
programming to heat the plate reader itself to 37°C and wait 5 minutes before
analysis. The results from this methodology are shown in Figure 33. The figure
shows how the top on method with incubation is not quite as good as the top off
method; however, the results are much better than when using the top on method
without the incubation. It is suggested to always use the top on and incubated
method if a sterile procedure is desired. If sterility is not an issue, the top off method
produces better results.

127

Figure 33: Top on and incubation method where a uniform 96 well plate was read
with its top on after an incubation within the multiwell plate reader showing the
distribution of variance amongst a uniform sample.

7.2 Resazurin Based Assay Toxicity
7.2.1 Introduction
Metabolic activity assays, including resazurin, are key determinants in
assessing the state of culture systems. Resazurin, or alamarBlue®, is generally
nontoxic during typical, manufacturer-recommended assay incubation times of a
few hours (292) (293). However, some studies deviate from these shorter time
periods (294). Resazurin is the fully oxidized active component in alamarBlue®,
which is blue and nonfluorescent (292) (293). Resazurin undergoes a redox
reduction reaction to resorufin, a pink, fluorescent chemical (79). The redox
reaction in resazurin-based assays provides information about the intercellular
processes and metabolic activity.

Under typical assay conditions, the active

128

component, resazurin, is reduced to resorufin (295). This chemical change,
changes the physical properties of the medium allowing detection via fluorescence
or spectrophotometry. However, if the assay is incubated too long, resorufin will
further reduce to hydroresorufin, a product of the second reduced state (296).
Caution must be taken to avoid incubation times leading to the production of
hydroresorufin as this product is nonfluorescent and colorless and will interfere
with colorimetric or fluorescent assays.
Although only commercially available since 1993 (297), resazurin detection
systems have been investigated since at least 1934 (298). During this time, few
people have noted toxic effects. Motivation for this study originated from the desire
to use resazurin as an in situ assay for testing tissue engineered cellular systems
over time, rather than as an endpoint assay.

7.2.2 Materials and Methods
Resazurin was tested with MCF7 (HTB-22™), MCF10A (CRL-10317™),
3T3-L1 (CL-173™), and D1 (CRL 12424™) cell lines from the ATCC (Manassas,
VA). MCF7 cells are human epithelial mammary adenocarcinomas cells, MCF10A
cells are human epithelial mammary fibrocystic cells, 3T3-L1 cells are mouse
embryonic fibroblast stem cells, and D1 cells are mouse bone marrow
mesenchymal stem cells. alamarBlue® (Invitrogen, Grand Island, NY) was used as
the resazurin source. Medium for the MCF7s, was Dulbecco’s Modified Eagle’s
Medium (ATCC) supplemented with 10% fetal bovine serum (Cellgro, Manassas,
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VA), 1% antibiotic-antimycotic (Cellgro), 1% fungizone (Cellgro), and 0.01mg/ml
insulin (Gibco, Grand Island, NY). Medium for the MCF10A cell line was
Dulbecco’s Modified Eagle’s Medium (ATCC) supplemented with 10% fetal bovine
serum (Cellgro) and Singlequots (Lonza, Basel, Switzerland). Media for the 3T3L1 and D1 cell lines were Dulbecco’s Modified Eagle’s Medium (ATCC)
supplemented with 10% fetal bovine serum (Cellgro), 1% antibiotic-antimycotic
(Cellgro), and 1% fungizone (Cellgro).
All cells were seeded at a density of 10,000 cells/ml in each well of four 96well plates (Greiner Bio-one, Monroe, NC). Each well was filled with 200µL of
medium specific to each cell type. The plates were incubated for three days in a
37°C and 5% CO2 incubator. After the initial seeding time, the wells were changed
with new media which were supplemented with concentrations of resazurin ranging
from 0% to 20% (v/v) of stock alamarBlue® solution to medium. Two of the seeded
plates were then incubated at 37°C and 5% CO2 for 3 hours, while one plate was
incubated for 4 days, and the last plate was incubated for 8 days. Medium was
changed every 2 days.
After the time points were reached for each plate, the treated medium was
removed and replaced with fresh medium free of any resazurin. Cells where then
incubated for 2 days further to preform assays. This additional two days of
incubation should have allowed assays to get insight into each condition and cell
type while they are equally unstressed. The importance of the additional days is
shown in Chapter 4.
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After the two additional recovery days, the medium was removed and stored
while fresh medium was added. An MTT assay (Invitrogen) was performed by
adding 100 μL medium + 10 μL of 12mM MTT stock solution to each well. The
plates were incubated for 3 hours per protocol instructions. The 3-hour time point
plates used the sodium-dodecyl-sulfate (SDS) method, where 100 μL of 350mM
SDS was added to the plates, while the 4-day and 8-day plates used the dimethyl
sulfoxide (DMSO) method, where 100 μL of DMSO was added to the plates. To
reduce bubbles which would obstruct the spectrophotometer, 100 μL of the 210 μL
solution in each well was removed and added to black-walled 96-well plates. These
black-walled 96-well plates were assessed in a SynergyMX multi-well plate reader
(Biotek,Winooski,VT). The SDS method plates were observed at 570λ while the
DMSO method plates were observed at 540 λ.
Two more assays were performed in addition to the metabolic activity
assessment. Wells were rinsed in phosphate buffered saline and loaded with
200µL 1X TE buffer (Invitrogen). The plates were then subjected to three cycles of
freezing and thawing, with an hour between each step. Quanti-IT PicoGreen®
(Invitrogen) assay was then performed on each well per manufacturer instructions.
A third assay measured the glucose levels in the medium at each medium change
with a YSI 2900 Biochemistry Analyzer (YSI Life Sciences, Yellow Spring, OH).
Four acellular blanks per cell line were used as the control for the glucose uptake
calculations.
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7.2.3 Results and Discussion
Resazurin, purchased as alamarBlue®, was tested in culture with a
mammary epithelial adenocarcinoma cell line, MCF7,

a non-tumorigenic

mammary epithelial fibrocystic cell line, MCF10A, a mouse embryonic fibroblast
stem cell line, 3T3-L1, and a mouse bone marrow mesenchymal stem cell line, D1.
Metabolic activity of the cell cultures after 4 and 8 days of culture with various
amounts of resazurin are shown in Figure 34. These data suggest lower cell
survivability with increasing concentrations of resazurin for MCF7, 3T3-L1, and D1
cell lines. Results from a two-tailed Student’s t-test of equal variance suggest
MCF7, 3T3-L1, and D1 cultures with 20% resazurin were significantly less
metabolically active than cultures with 0% resazurin after 8 days in the medium (Pvalue < 0.05). No statistical claim can be made regarding the MCF10A cell line
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.
Figure 34: Metabolic activity after 4 and 8 days of culture with alamarBlue
concentrations listed. The assay was conducted after a 2-day recovery period in
fresh alamarBlue free medium, then an MTT assay was performed. Three repeats
were conducted per condition. Bars illustrate two standard deviations or 99.5%
certainty.
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Figure 35: DNA concentrations after 4 and 8 days of culture with alamarBlue
concentrations listed. The assay was conducted after a 2-day recovery period in
fresh medium. Two repeat assays were conducted per condition. Bars illustrate
two standard deviations or 99.5% certainty.
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To investigate the apparent reduction in cellular metabolism, DNA
concentration was measured for each sample. These data are shown in
Figure 35. and appear to follow the general patterns seen in Figure 34. A two-tailed
equal variance Student’s t-test reveals that the DNA concentrations of MCF7, and
D1 cultures supplemented with 20% resazurin were significantly different from that
of un-supplemented cultures after 8 days (P-value < 0.05). This suggests the cells
were less numerous in cultures with resazurin. No statistical comparisons can be
made for MCF10A cultures based on DNA concentration. A two-tailed equal
variance Student’s t-test on 3T3-L1 at day 4 shows cultures supplemented with
20% resazurin were significantly different from un-supplemented cultures (Pvalues <0.05).
Values shown in Figure 36 and Figure 37 are the glucose levels of blanks
minus cellular sample glucose levels.

The glucose uptake calculation was

performed on the medium at each medium change. These data are perhaps the
most informative. A two-tailed Student’s t-test, shows MCF7, 3T3, and D1 with
either 5%, 10% or 20% resazurin in medium used less glucose than untreated
controls. Statistical claims cannot be made for MCF10A cells.

135

Figure 36: Glucose uptake results at each day of media change. Cultures with
alamarBlue were used at concentrations listed. Day 10 measurements were made
after a 2-day recovery period in fresh medium. Five repeats per condition. Bars
illustrate two standard deviations or 99.5% certainty.
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Figure 37: Glucose uptake results at each day of media change. Cultures with
alamarBlue were used at concentrations listed. Day 10 measurements were made
after a 2-day recovery period in fresh medium. Five repeats per condition. Bars
illustrate two standard deviations or 99.5% certainty.
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These data suggest resazurin-based assays are toxic to several cell lines.
It cannot yet be said which state of resazurin is causing this effect, but it is worth
investigating. It is known that both resazurin, and its reduced state, resorufin, were
in contact with the cells. It cannot be said if the twice reduced state of resazurin,
hydroresofuin, was in contact with the cells. However, it is imperative for users of
resazurin-based, non-destructive in vitro assays to be aware of potential longerterm toxic effects caused by resazurin or its reduced states, and to be aware that
different cell types may have differing levels of tolerance for resazurin.
Since resazurin-based assays have been shown to have toxic effects over
longer than manufacturer-recommended incubation times, the recommended
shorter incubation times were investigated. Cells were treated using the
manufacturer’s recommendation of 10% alamarBlue stock solution for 3 hours.
After the assay incubation time, the medium was refreshed and the cells were
cultured for 2 more days, then the metabolic activity, glucose, and DNA levels were
measured (Figure 38). There is no statistical difference between control and
sample results for any of the cell lines. These results support the manufacturer’s
claim that the assay is non-destructive during the recommended assay times.
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Figure 38: This figure shows three assays performed on cell cultures which had
undergone an alamarBlue assay following the manufacturer’s recommended
concentrations and times. The assays were conducted after a 2-day recovery
period in fresh medium. The spent glucose is that of the recovery medium. Ten
repeats per condition. Bars illustrate two standard deviations or 99.5% certainty.
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7.2.4 Conclusions
Resazurin, introduced as a cell viability indicator under the trade name
alamarBlue®, is generally regarded as nontoxic when used according to the
manufacturer’s suggested shorter-term incubation time specifications. However,
problems arise when exposure times are extended to longer-term cultures on the
order of days. To assess the effect of resazurin over longer incubation times,
MCF7 (HTB-22), MCF10A (CRL-10317), 3T3-L1 (CL-173), and D1 (CRL-12424)
cultures were tested with varying amounts of resazurin over 4- and 8-day periods.
MCF7, 3T3-L1, and D1 cells cultured for 8 days with 20% alamarBlue® had
significantly less cell survivability. Specifically, levels of metabolic activity,
deoxyribonucleic acid (DNA) concentration, and glucose consumption of the cell
lines cultured for 8 days in medium with 20% alamarBlue® were significantly lower
(p<0.05) than metabolic activity, DNA concentration, and glucose consumption of
MCF7 cells cultured for 8 days in medium with no alamarBlue®. MCF7, 3T3-L1,
and D1 cells used less glucose at concentrations as low as 5%. Data also suggests
the toxic effects are more pronounced in the cancerous cell line as compared to
the noncancerous cells
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7.3 Gas Chromatography Methodology Improvement
7.3.1 Introduction
Gas chromatography offers the ability to detect individual isomers of fatty
acids through column separation and flame ionization detection (299).
Triglycerides and fatty acids must be chemically processed to fatty acid methyl
esters (FAME) before they can be quantified via gas chromatography. In typical
FAME production, the fat substrate is subjected to an alkali-catalyzed
transesterification step, shown in Figure 39 (300). However, when free fatty acids
are included in the substrate, the catalyst reacts with the free fatty acids to form
soaps. The soaps then form emulsions, which hamper further liquid-liquid
extraction purification steps (300).
Once fatty acid methyl esters have been produced and run on the gas
chromatography, a calibration curve is needed. Calibration standards can be
purchased from commercial sources; however, an internal standard is required to
account for inter-sample variability during the chemical modifications. The internal
standard is frequently C19:0 or C23:0. The previous protocol required the internal
standard to be added after lipid extraction but before transesterification. This many
not be ideal for accounting for all the inter-sample variability. A unique procedure
which does not use saponification catalysts, and a procedure which better uses
internal standards is needed before this assay can be used for experimental
purposes.
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Figure 39: Reaction scheme for the production of methyl esters from triglycerides
and methanol.

7.3.2 Transesterification and Esterification
The

typical

FAME

production

technique

is

a

base-catalyzed

transesterification reaction of triglycerides with sodium hydroxide in the presence
of excess methanol (300). This involves the displacement of alcohol from one ester
to another. In this process, a triglyceride molecule reacts with an alcohol to form
the monoesters of fatty acid methyl esters. When the three chains of a triglyceride
are removed to form esters, the glycerin backbone is all that remains and no soap
compounds (301). This mechanism is shown in Figure 39. However, when free
fatty acids are present, the sodium hydroxide will cause saponification and prevent
the detection of fatty acids in the gas chromatography. An additional step should
be added before the base-catalyzed transesterification.
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The most common method for the production of FAMEs from free fatty acids
involves the addition of excess methanol with a strong acid, usually sulfuric acid.
The acid catalyzes an esterification reaction of the free fatty acids to FAMEs. Acid
catalysts can also eventually convert triglycerides into fatty acid methyl esters;
however, the reaction is too slow to be practical (301). Thus, an acid-catalyzed
pretreatment step of methanolic hydrochloride is suggested to precede an alkalicatalyzed reaction of sodium methoxide to convert both the triglycerides and free
fatty acids into FAMEs without unintentional saponification. Sodium methoxide is
suggested as a replacement for sodium hydroxide to further limit the degree of
saponification; however, care must be taken due to the explosive nature of sodium
methoxide.

7.3.3 Dipole Moments and Toluene
The hydrophobic and solubility natures of chemicals are sometimes thought
of as absolutes; however, the truth is more dynamic. Compounds have varying
degrees of water solubility due, in part, to their dipole moments. A graphical
comparison of dipole moments are shown in Figure 40 for a simple molecule.
Moving from left to right, methane (CH4) has no dipole moment and is very water
insoluble, Chloromethane (CH3Cl) has a large dipole moments and is very watersoluble. The rest, methylene chloride (CH2Cl2), chloroform (CHCl3), and carbon
tetrachloride (CCl4) have varying degrees of hydrophobicity where higher dipole
moments correlate to larger degrees of water solubility.
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Figure 40 Depiction of dipole moments as it relates to chloroform and others
The molecules in question for use in this gas chromatography procedure
are hexane, toluene, water, and methanol. Water’s dipole moment is 1.85D, and
will join the phase with the largest dipole moment. Methanol’s is 1.69D and will
almost exclusively go into the water, or aqueous, phase. Hexane has a dipole
moment of 0.08D, making it very resistant to join the aqueous phase. Its solubility
in water is 9.5mg/L before saturation. Hexane’s density is 0.655g/mL and there for
has a solubility of 0.0145 mL/mL.
Toluene is an aromatic compound, meaning it has a ring of delocalized πorbital electrons. This gives toluene a unique property that the other chemicals in
question do not have. Toluene has a dipole moment of 0.31D. The electron density
of toluene is shown in Figure 41. This mid-range dipole moment means toluene
will be significantly spilt between solubility between the aqueous and organic
phases. Toluene has a max solubility in water at room temperature of 470 mg/L.
Toluene’s density is 0.867 g/mL. Therefore, toluene’s solubility in water is 0.542
mL/mL
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.
Figure 41 Toluene electron density
In a typical liquid-liquid extraction, as shown in Figure 42, there is a two
phase system where the top phase is organic and the bottom phase is aqueous.
The previous protocol called for the addition of 0.5 mL internal standard solvent, 5
mL methanol, 1mL hexane, and 7.5 mL salt water. The intent of the high salt
content was is to increase the effective dipole moment of the aqueous phase to
‘salt out’ the desired methylated fatty acids to the organic phase.
When the previous procedure was used, the 0.5mg of internal standard,
nonadecanoic acid, was added with hexane. The added hexane would mostly
come out in top organic phase during to final separation. The total balance became
12.5mL aqueous phase and 1.5mL hexane. With hexane’s solubility being 0.0145
mL/mL as calculated previously, only 0.18 mL of hexane would be dissolved in the
water phase and the remainder would form the organic phase, meaning the
organic phase contained approximately 1.32 mL hexane and 0.5 mg of
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nonadecanoic acid. The final concentration of internal standard became
0.378mg/mL rather than the desired 0.5mg/mL concentration.

Figure 42 Phase separation
To account for this phenomenon, toluene should be used. If toluene is used
instead of hexane, the 0.5mg of nonadecanoic acid is still introduced but giving
12.5mL aqueous, 1 mL hexane, and 0.5mL toluene. With toluene’s solubility as
0.542mL/mL this means 6.8mL of toluene could go into the bottom phase before
a significant amount goes into the top. This will yield approximately 1mL hexane in
top and the desired 0.5mg/mL concentration of internal standard. In summary, if
hexane were used as the solvent for internal standard, the ending concentration
would be 0.378mg/mL rather than the desired 0.5mg/mL. If toluene is used, this
problem is corrected.
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7.3.3 Conclusions
The gas chromatography procedure needs special procedures to account
for its use in tissue engineering. Specifically, the transesterifiation and
esterification procedures need to be performed without saponification inducing
catalysis, and done in proper order to avoid unintended soap production
consequences. Additionally, the internal standard addition should be introduced
with the addition of toluene rather than hexane to avoid dilution of the internal
control. The final suggested procedures are as follows:
•

Lipid extraction from aqueous cellular lysate

•

Evaporation of organic solvent

•

Addition of internal standard via toluene

•

Esterification catalyzed by methanolic HCl

•

Transesterfication catalyzed by sodium methoxide

•

Liquid-liquid extraction with hexane and brine
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CHAPTER 8
CONCLUSIONS
The goal of this work was to investigate the potential of fatty acids in breast
tissue engineering, work towards a lumpectomy void filler, and improve adipose
engineering techniques. A number of conclusions can be drawn from this body of
work. While linoleic acid is known to support tissue growth through eicosanoids,
its previously defined status of supporting cancerous growth prevented its use in
breast tissue engineering. However, work shown here challenges that idea, giving
support for the use of linoleic acid as a scaffolding additive. Specifically, the lipid
peroxidation potential for 100 µM linoleic acid (18:2 ω-6) was quantified in cell
culture for 6 to 8 days showing:;
•

MCF7 and MDA-MB-231 breast cancer cell cultures exhibited less
proliferation and metabolic activity when cultured with 100 µM linoleic acid.

•

MCF7 and 4T1 breast cancer cell cultures were indistinguishable from
acellular controls by 8 days when cultured with 100 µM linoleic acid.

•

Breast cancer cells had no consistent effect from 25 µM linoleic acid.

•

PCS-210-010 preadipocytes and MCF10A breast cells showed no
constant effect from 25 µM or 100 µM linoleic acid.

•

The lipid peroxidation product malondialdehyde was detected and found
to be at a significantly higher concentration in cancerous cells with 100µM
linoleic acid while not observed in healthy control cells.
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Previous literature suggests other polyunsaturated fatty acids may work in
combination with free radial inducing chemotherapeutics. Tamoxifen is frequently
used in post-lumpectomy patients, and its interaction with linoleic acid should be
determined. Tamoxifen is not primarily known to function by free radicals; however,
limited research suggested tamoxifen may alter mitochondrial membrane stability,
which is a key factor in lipid peroxidation. Conclusions from research on the
combined effects of 6 days of culture with tamoxifen and 100 µM linoleic acid show:
•

Linoleic acid was more effective at the inhibition of MCF7 breast cancer
proliferation than tamoxifen.

•

The combined treatment of tamoxifen and linoleic acid was more effective
than either compound alone.
While linoleic was shown to be highly effective has a potential scaffolding

additive, other fatty acids may have potential as well. Specifically, conjugated
linoleic acid has been shown to be anti-cancerous through lipid peroxidation as
well but lacks the relationship to growth-inducing eicosanoid synthesis. In fact,
conjugated linoleic acid acts as an inhibitor of eicosanoid synthesis. Some isomers
of conjugated linoleic acid have been shown to upregulate adipogenic markers
while others have been shown to antagonize adipogenic gene expression.
Currently available conjugated linoleic acid supplements for the medical field
include an equal mixture of the c9t11 and t10c12 isomers of conjugated linoleic
acids. Work was done to determine if a mixture of conjugated linoleic acid could
upregulate adipogenic differentiation markers. Conclusions that can be drawn are
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•

Concentrations over 200 µM conjugated linoleic acid were found to be toxic
to human mesenchymal stem cells.

•

Morphological changes to human mesenchymal stem cells after 12 days of
culture with 100 µM conjugated linoleic acid was found to be similar to
changes in adipogenic controls

•

The mRNA expression levels of aP2, C/EBPα, and PPAR-γ from human
mesenchymal stem cells cultured with 100 µM conjugated linoleic acid for
12 days were found to be upregulated from control values and not
significantly different from adipogenic controls.
With the potential for these fatty acids shown, work was done towards the

development of a biodegradable scaffolding for used in lumpectomy patients. A
method was developed which created a bilayered chitosan, gelatin, and
hyaluronan scaffolding which had unique cell growth properties. Specific
conclusions which can be drawn are that:
•

The creation of a bilayered hydrogel bead is possible where the cells attach
and proliferate between the layers shielded from shear stresses.

•

The proliferation rates of murine mesenchymal stem cells were found to be
higher in bilayered hydrogels when compared to uniform controls.

•

The presence of a bilayer was confirmed through the use of a hydrogel
specific histology technique.
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•

The inclusion of free fatty acids into the production process of the bilayered
hydrogel scaffolding was found to be possible at concentrations up to 400
µM.

•

An elution study rejected the hypothesis that the bilayer may retard fatty
acid diffusion from the hydrogel beads.
Through the course of this body of research, several advances were made

in the field of test methods for tissue engineering. Work was done towards the
improvement of procedures of multiwell plate readers to allow sterile sampling, the
cytotoxicity of alamarBlue was found and investigated, improvements to previous
lab gas chromatography procedures were made, and analysis of experimental
results indicate the importance of recovery periods in cytotoxicity studies. Specific
conclusions which can be drawn are:
•

Moving a cell culture plate directly from a 37°C humid cell culture incubator
to a spectrophotometer for analysis resulted in the induction of up to 60%
error in sample readings from water droplet formation.

•

Programming the spectrophotometer to use its built-in oven feature and
including a 5 minute wait time before analysis removed the inducted error
from water droplet formation.

•

Resazurin based assays, such as alamarBlue, were found to be cytotoxic if
used in cell culture with as little as 5% for 4 days.

•

Resazurin-based assays were found to have no significant lasting effect if
used within the manufacturer’s specified time frame.
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•

The cytotoxicity of resazurin-based assays, which operate based on
mitochondrial function, was found to be more potent towards the inhibition
of MCF7 cancerous cells than other cell lines.

•

When performing methylation reactions on samples for use in gas
chromatography to detect free fatty acids, the internal standard should be
added with toluene before an esterification reaction catalyzed by methanolic
HCL, followed by a transesterification catalyzed by sodium methoxide.
Additionally sodium hydroxide should not be used to avoid a saponification
reaction.

•

The metabolic activity of treated cell cultures is raised within treatment
media; however, analysis after a two-day rest period reveals more insightful
information.
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CHAPTER 9
RECOMMENDATIONS
The scope of this body of work was limited to initial development of a
scaffolding production technique as well as to the investigation into the potential
for fatty acids to act as tissue scaffolding additives. Based on the findings of this
work, future research directions are suggested
•

Additional in vitro studies of linoleic acid’s effect on cancerous cell growth
is warranted. Cocultures of healthy cells and fluorescent transfected
cancerous cells should be tested on an extended timeline with 100 µM to
determine if any cancerous cells are present after a given time.

•

Future

researchers

should

seek

to

include

recently

developed

immunofluorescent-based assays to detect newly synthesized eicosanoids.
(302)
•

Further research should be performed to determine at what concentration
or time points linoleic acid becomes cancer-inducing, as literature suggests.
Data shown here suggest linoleic acid had no effect at 25 µM and 6 days.

•

It is recommended that lipid peroxides are investigated in other oncology
fields. Given the unique membrane properties of neurological cells, fatty
acids and their lipid peroxidation products may have a use in neurological
cancer treatment.

•

It should be determined whether lipid peroxides are cytotoxic through DNA
intercalation or through membrane disruption.
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•

Further improvements to the bilayered scaffolding design are needed if fatty
acids are to be retained on a scale relevant for clinical use. Specifically,
work should be done to evaluate replacements for hyaluronic acid with other
biodegradable anionic polymers. Specifically, the use of lipophilic anionic
polymers may also be useful for the retention of fatty acids.

•

The mechanism by which cells migrate through the outer layer and attach
to the chitosan inner spherical core should be investigated. Data shows
small tube-like formations in this outer layer of hydrogels when grown in cell
culture. The samples could be investigated by SEM or other imaging
methods.

•

Research with animal models should be performed. Sections in the
literature review outline mechanisms for cancerous induction and
appropriate animal model choices. The implanted lumpectomy scaffolding
should be loaded with tamoxifen, linoleic acid, and conjugated linoleic acid.
The histological samples should investigate the degree of fibrous
encapsulation, tissue ingrowth, and cancerous cell populations against
controls.

•

Future test method innovations may investigate the use of resazurin to
detect radical generation. The current lipid peroxide assays only detect
byproducts and are destructive. Resazurin assays are known to function by
redox reactions from free electrons from the electron transport chain.
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Perhaps the assay could be used as a nondestructive assay for the
detection of free electrons from lipid peroxides.
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